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Abstract
G protein-coupled receptors (GPCRs) are a class of integral membrane receptor
proteins that are characterized by seven-transmembrane (7TM) domains connected by
intracellular and extracellular loops, an extracellular N-terminus, and an intracellular Cterminus. GPCRs recognize neurotransmitters, sensory molecules and chemotactic agents
and are involved in the control of many aspects of metabolism. Since GPCRs play
important roles in diverse processes such as pain perception, growth and blood pressure
regulation, and viral pathogenesis, GPCRs became important target for therapeutic
agents. The tridecapeptide α-factor pheromone (W1H2W3L4Q5L6K7P8G9Q10P11M12Y13) of
Saccharomyces cerevisiae and Ste2p, its cognate GPCR, have been used extensively as a
model for peptide ligand-GPCR structure and function. The power of yeast genetics has
been used to examine the structure and function of Ste2p. Recently, GPCR homodimerization has been demonstrated for many GPCRs, although the role(s) of
dimerization in receptor function is disputed. In this dissertation, Ste2p has been used to
investigate GPCR dimerization.
Part I of this dissertation is an overview of the GPCR structure and its ligandinduced conformational change with specific emphasis on the peptide pheromone αfactor and its receptor Ste2p. Part II of this dissertation is a study originally designed to
probe inter-helical interaction between TM1 and TM7 of Ste2p. Site-directed
mutagenesis and cysteine cross-linking with targeted residues of Ste2p were carried out.
Although the anticipated inter-helical interactions were not identified from this study, the
results provided strong evidence for Ste2p dimerization. Part III of this dissertation
describes dimer interfaces including TM1 and TM7 of Ste2p. By using the disulfide
iii

cross-linking methodology, we studied the participation of specific residues at the
intracellular boundary between TM1 and intracellular loop one and the entire TM7 in
Ste2p dimerization. The final part of this dissertation contains a study of the participation
of the Ste2p N-terminus in homo-dimer formation and the effect of ligand binding on this
interaction. This part also includes overall conclusions and suggestions for future
experiments that could contribute to an understanding of the dimer interfaces in Ste2p
and the role of dimerization in the function of this receptor.

iv

Table of Contents
PART I GENERAL INTRODUCTION ........................................................................ 1
CHAPTER 1 G PROTEIN-COUPLED RECEPTORS ............................................................. 2
An overview................................................................................................................ 2
Classification of GPCRs ............................................................................................. 3
The tertiary structure of GPCRs ................................................................................. 7
Ligand binding and receptor activation .................................................................... 12
Conformational Changes Involved in Agonist Induced GPCR Activation .............. 13
Intramolecualr interaction of TMs and TM movements during receptor activation 15
CHAPTER 2 α-FACTOR PHEROMONE AND ITS G PROTEIN-COUPLED RECEPTOR (STE2P)
IN SACCHAROMYCES CEREVISIAE...................................................................................... 19

GPCRs in fungi ......................................................................................................... 19
α-factor Pheromone and its G Protein-coupled receptor (Ste2p) in Saccharomyces
cerevisiae .................................................................................................................. 21
Mating in yeast, Saccharomyces cerevisiae.............................................................. 21
Regulation of Ste2p in Saccharomyces cerevisiae and protein Signaling................ 23
Structure-function analysis of α-factor pheromone.................................................. 27
CHAPTER 3 OLIGOMERIZATION OF GPCR.................................................................. 34
An overview.............................................................................................................. 34
Dimer-/Oligomerization of Ste2p ............................................................................. 38
LIST OF REFERENCES FOR PART I................................................................................... 41

v

PART II STUDY OF INTER-HELICAL INTERACTION BETWEEN
TRANSMEMBRANE DOMAIN 1 AND 7 OF STE2P ............................................... 62
CHAPTER 1 ABSTRACT ............................................................................................... 63
CHAPTER 2 INTRODUCTION ........................................................................................ 64
CHAPTER 3 EXPERIMENTAL PROCEDURES .................................................................. 67
Strains, Media, and Plasmids .................................................................................... 67
Growth Arrest (Halo) Assay ..................................................................................... 68
FUS1-lacZ Gene Induction Assay ............................................................................ 68
Preparation of membranes ........................................................................................ 69
Disulfide Cross-linking with Cu-Phenanthroline...................................................... 69
Factor Xa digestion ................................................................................................... 70
Western blot .............................................................................................................. 70
CHAPTER 4 RESULTS.................................................................................................. 71
Expression and Biological Activities of Double Cys Mutant Receptors.................. 71
Identification of Inter-molecular interaction between TMs using Factor Xa digestion
................................................................................................................................... 76
CHAPTER 5 DISCUSSION ............................................................................................. 85
LIST OF REFERENCES FOR PART II ................................................................................. 87
PART III IDENTIFICATION OF SPECIFIC TRANSMEMBRANE RESIDUES
AND LIGAND-INDUCED INTERFACE CHANGES INVOLVED IN HOMODIMER FORMATION OF A YEAST G PROTEIN-COUPLED RECEPTOR ...... 93
CHAPTER 1 ABSTRACT ............................................................................................... 94
vi

CHAPTER 2 INTRODUCTION ........................................................................................ 95
CHAPTER 3 EXPERIMENTAL PROCEDURES .................................................................. 97
Strains, Media, and Plasmids .................................................................................... 97
Growth Arrest (Halo) Assay ..................................................................................... 98
FUS1-lacZ Gene Induction Assay .......................................................................... 100
Preparation of membranes ...................................................................................... 100
Disulfide Cross-linking with Cu-Phenanthroline.................................................... 101
Factor Xa digestion ................................................................................................. 102
Saturation Binding assay with [3H]α-Factor........................................................... 102
Western blot ............................................................................................................ 102
HIS-select HC Nickel affinity................................................................................. 103
MTSEA Labeling.................................................................................................... 104
CHAPTER 4 RESULTS................................................................................................ 105
Expression and Biological Activities of Cys Mutant Receptors............................. 105
Dimerization of Some Cys Mutants in TM1 and TM7 Is Markedly Enhanced by the
Oxidizing Reagent Cu (II)-1, 10-Phenanthroline.................................................... 114
Effect of Ligand Addition on Dimerization............................................................ 125
CHAPTER 5 DISCUSSION ........................................................................................... 133
LIST OF REFERENCES FOR PART III .............................................................................. 148
PART IV PARTICIPATION OF THE STE2P N-TERMINUS IN HOMO-DIMER
FORMATION AND THE EFFECT OF LIGAND BINDING ON THIS
INTERACTION............................................................................................................ 158
CHAPTER 1 INTRODUCTION ...................................................................................... 159
vii

CHAPTER 2 EXPERIMENTAL PROCEDURES ................................................................ 161
Strains, Media, and Plasmids .................................................................................. 161
Preparation of membranes ...................................................................................... 161
Disulfide Cross-linking with Cu-Phenanthroline.................................................... 162
Western blot ............................................................................................................ 162
CHAPTER 3 RESULTS................................................................................................ 163
CHAPTER 4 DISCUSSION ........................................................................................... 171
CHAPTER 5 SUMMARY AND FUTURE DIRECTION ...................................................... 173
Summary ................................................................................................................. 173
Whole cell, In vivo, cross-linking........................................................................... 174
Study of receptor function and dimer relationship ................................................. 177
Relationship of Dimers to Glycosylation State of Ste2p ........................................ 178
Study for higher order oligomer of Ste2p ............................................................... 179
Investigation of dimer formation pattern of TM7 mutants in C-terminal tail truncated
Ste2p ....................................................................................................................... 180
LIST OF REFERENCES FOR PART IV .............................................................................. 181
VITA............................................................................................................................... 187

viii

List of Tables
Table 1 Examples of Top-selling GPCR drugs in 2005 ..................................................... 4
Table 2 Sequence-based groupings within the G-protein-coupled receptors ..................... 6
Table 3 Six classes of GPCRs in fungi ............................................................................. 20
Table 4 Proposed roles of GPCR dimerization/oligomerization ...................................... 35
Table 5 Structural domains reported to be involved in GPCR
dimerization/oligomerization............................................................................................ 37
Table 6 Biological Activities of double Cys mutants ....................................................... 74
Table 7 Receptors used in this study................................................................................. 99
Table 8 Biological activities of Cys mutant receptors .................................................... 112
Table 9 Effect of ligand binding on Cu-P (Cu (II)-1, 10-phenanthroline) stimulated
disulfide bond formation1 ............................................................................................... 115
Table 10 Effect of NEM on Cu-P(Cu (II)-1, 10-phenanthroline) stimulated disulfide bond
formation1 ....................................................................................................................... 118
Table 11 Cysteine labeling of selected mutants.............................................................. 143

ix

List of Figures
Figure 1 Classification of human GPCRs........................................................................... 9
Figure 2 Panel of Representative GPCRs Solved to Date ................................................ 14
Figure 3 Possible mechanisms how agonist binding disrupts intramolecular interactions
that stabilize the inactive state. ......................................................................................... 18
Figure 4 Pheromone mediated mating in Saccharomyces cerevisiae ............................... 24
Figure 5 Saccharomyces cerevisiae mating pathway........................................................ 25
Figure 6 Functional domains of α-factor ligand ............................................................... 31
Figure 7 Working model for fitting of the α-factor pheromone into a ligand binding site
on its GPCR Ste2p ............................................................................................................ 32
Figure 8 A. The two-dimensional topology of Saccharomyces cerevisiae Ste2p and B.
Dose-response analysis of growth arrest assay................................................................. 72
Figure 9 Expression of double Cys mutant receptors ....................................................... 77
Figure 10 2D diagram illustrated expected result for interaction ..................................... 80
Figure 11 Factor Xa digestion of FT-HT-Xa.................................................................... 81
Figure 12 Factor Xa digestions of double cysteine containing Ste2p receptors ............... 82
Figure 13 Effect of Cu-P [Cu (II)-1, 10-phenanthroline] treatment on receptors containing
two cysteine replacements ................................................................................................ 84
Figure 14 The two-dimensional topology of Saccharomyces cerevisiae Ste2p ............. 107
Figure 15 Effect of Cu-P (Cu (II)-1, 10-phenanthroline) treatment on the dimerization of
Ste2p containing single cysteine mutations .................................................................... 109
Figure 16 Protease Factor Xa digestions of single cysteine containing Ste2p receptors121
Figure 17 Pull-down assay............................................................................................. 123
x

Figure 18 Effect of Cu-P (Cu (II)-1, 10-phenanthroline) treatment on FT-HT-Xa
containing cysteine replacements in TM7 ...................................................................... 127
Figure 19 Time course analysis of dimer formation at the residues C-terminal to P290 of
TM7................................................................................................................................. 129
Figure 20 Effect of ligand binding on Cu-P (Cu (II)-1, 10-phenanthroline) stimulated
disulfide bond formation................................................................................................. 130
Figure 21 Time course cross-linking of V68C ............................................................... 132
Figure 22 Dimerization interfaces of Ste2p .................................................................... 135
Figure 23 Representation of cross-linking results of TM7 and helical wheel presentation
of TM1 and TM7 in Ste2p .............................................................................................. 139
Figure 24 Cysteine labeling of selected mutants ............................................................ 142
Figure 25 Dimer formation of Cys mutants.................................................................... 166
Figure 26 The percent of dimer formed by each Cys mutant ......................................... 168
Figure 27 Effect of ligand binding on Cu-P [Cu (II)-1, 10-phenanthroline] stimulated
disulfide bond formation................................................................................................. 169
Figure 28 Reaction of maleimide-activated compounds to sulfhydryls ......................... 176

xi

PART I General Introduction
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CHAPTER 1 G Protein-Coupled Receptors
An overview
G protein-coupled receptors (GPCRs) are a class of membrane receptor
proteins that are characterized by a signature seven-transmembrane domain (7TM) and
heterotrimeric guanine nucleotide-binding proteins (G proteins) coupled to receptor [1].
GPCRs consist of large and diverse gene families found in fungi, plants, and the animal
kingdom. In humans, GPCRs comprise the largest superfamily of proteins with more than
1000 different GPCRs identified [2]. GPCRs are located at the cell surface and are
responsible for the transduction of an extracellular stimulus into an intracellular response
[3]. The endogenous ligands of GPCRs are extraordinarily diverse, including biogenic
amines (such as adrenaline, dopamine, histamine, and serotonin), peptide and protein
hormones (for example,angiotensin, bradykinin, endothelin, and melanocortin), peptide
pheromones (i.e. α-factor, a-factor of various fungal species), nucleosides and
nucleotides (adenosine, adenosine triphosphate, uridine triphosphate), and lipids and
eicosanoids (cannabinoids, leukotrienes, prostaglandins, and thromboxanes) [4].
Furthermore, the awareness of exogenous signals, such as light, odor, and taste, is also
mediated via GPCRs [5, 6]
Heterotrimeric G proteins are regulated by GPCRs upon ligand binding to
receptors. G proteins are composed of three subunits (α, βγ-dimer) and each subunit
plays important roles in determining the specificity and temporal characteristics of the
cellular responses to signals [7]. Conformational change of receptor accompanied by
activation of GPCRs lead to release of GDP followed by binding of GTP of Gα-subunit
2

[1]. This change triggers the dissociation of the α-subunit from the receptor and the βγdimer. Both the GTP bound α-subunit and the released βγ-dimer can mediate the
stimulation or inhibition of effector proteins such as enzymes and ion channels [e.g,
adenylate cyclase, guanylyl cyclase, phospholipase C, mitogen-activated protein kinases
(MAPKs), Ca+2, and K+ channels]. Thus, stimulation of GPCRs with specific agonists
results in changes in the concentration of second-messenger molecules [1]
Considering the wide variety of biological pathways regulated by GPCRs it is not
unexpected that abnormal signaling by these receptors lead to disorders in tissues and
organs in the human body [8]. Currently, GPCRs are ideal drug target for pharmaceutical
companies due to the widespread physiological processes GPCRs mediated.
Approximately 50% of all modern prescription drugs and 25% of the top-selling drugs
directly or indirectly have an effect on GPCRs [3, 6, 9] (Table 1). However, only a very
small portion of the known GPCRs represent targets of currently marketed drugs. Many
GPCRs remain ‘orphan’, which have not been assigned functions. Even for many
receptors whose ligands are known, there is a need for identifying agonist and antagonist
ligands. Regarding these facts, it is suggested that GPCRs will continue to be drug targets
of the future [10-12]. Thus, the studies of GPCRs will contribute significantly to the
understanding and treatment of a variety of diseases.

Classification of GPCRs
Despite the fact that various agonists stimulate the special GPCR family to
activate diverse secondary-messenger pathways, GPCRs share structural similarities [13].
3

Table 1 Examples of Top-selling GPCR drugs in 2005
Action

Trade

Molecular

Name

Entity

Company

Therapeutic

World

Indication

Sales
(US$
millions)

H11

Allegra/

antagonist

Telfast

AT12

Fexofenadine

Sanofi-Aventis

Allergies

1792

Diovan

Valsartan

Novartis

Hypertension

2214

Gaster

Famotidine

Yananouchi

Gastric ulcer

656

Lmigran

Sumatriptan

GlaxosmithKline

Migraine

1454

LH-RH5

Leuplin/

Leuprorelin

Takeda/Abbott

Cancer

904

agonist

Lupron

GABAb6

Neuronti

GABApentin

Pfizer

Neurological

2480

agonist

n

Β1 agonist7

Serevent

Salmeterol

GlaxosmithKline

Asthma

679

Mixed

Zyprexa

Olanzapine

Eli Lilly

Schizophrenia

4905

antagonist
H23
antagonist
5HT104
agonist

pain

5HT28/D19/
D210
antagonist
Table modified from Jacoby et al [6].
1

H1, Histamin 1 receptor; 2 AT1, Angiotensin1 receptor; 3 H2, Histamin 2 receptor;

4

5HT10, Serotonin (5-hydroxytryptamine, 5-HT) 10 receptor; 5 LH-RH, Luteinizing

hormone-releasing hormone receptor; 6 GABAb, γ-Aminobutyric acid receptor; 7 Β1,
Bradykinin 1 receptor; 8 5HT2, Serotonin (5-hydroxytryptamine, 5-HT) 2 receptor; 9 D1,
Dopamine 1 receptor; 10 D2, Dopamine 2 receptor
4

All GPCRs contain seven transmembrane-spanning α-helical segments connected
by alternating intracellular and extracellular loops (IL and EL, respectively), with the
amino terminus located on the extracellular side of the cytoplasmic membrane and the
carboxy terminus on the intracellular side. Although GPCRs share common membrane
topological features, sequence comparisons showed little or no similarities among the
different GPCRs [14] and the size of the each domain vary such as extracellular Nterminal tails (7-600 amino acids), loop domains (5-230 amino acids), and C-terminal
domains (12-360 amino acids) which indicate diverse functions of GPCRs [7].
The GPCR superfamily has been classified into six different families. Each class
has at least 20 % identity of their amino acid sequence within the TMs (Transmembrane
domains) (Table 2)[4]. The rhodopsin-like class A receptor is the most studied because it
is easily obtainable in a purified form in large quantitites and it has the largest number of
receptors. This class contains receptors for peptides, hormone peptide, odorants, small
molecules such as the catecholamines and amines, and glycoprotein hormones (Fig.1 A)
[9]. Among class A receptors, peptide receptors are the largest subgroup and mediate
important physiological roles of endogenous peptides that act as neurotransmitters and
hormones. Class A receptors are characterized by a series of highly conserved key
residues such as the DRY motif at the bottom of transmembrane domain (TM) 3 and the
NPXXY motif in TM7 (Fig. 1 A). Class B receptors are the next largest class including
receptors for a variety of gastrointestinal peptide hormones (secretin, glucagons,
vasoactive intestinal peptide, and growth-hormone-releasing hormone), calcitonin,
corticotrophin-releasing hormone and parathyroid hormone [1]. Class B receptors do not
share any of the structural features characterizing class A receptors except for the
5

Table 2 Sequence-based groupings within the G-protein-coupled receptors
Class: A Rhodopsin-like receptors
Family I

Olfactory receptors, adenosine receptors,
melanocortin receptors, and others

Family II

Biogenic amine receptors

Family III

Vertebrate opsins and neuropeptide receptors

Family IV

Invertebrate opsins

Family V

Chemokine, chemotactic, somatostatin, opioids and others

Family VI

Melatonin receptors and others

Class B: Calcitonin and related receptors
Family I

Calcitonin and calcitonin-like receptors

Family II

PTH1/PTHrP2 receptors

Family III

Glucagon, secretin receptors and others

Family IV

Latrotoxin receptors and others

Class C: Metabotropic glutamate and related receptors
Family I

Metabotropic glutamate receptors

Family II

Calcium receptors

Family II

GABAb3 receptors

Family IV

Putative pheromone receptors

Class D: STE2 pheromone receptors
Class E: STE3 pheromone receptors
Class F: cAMP and archaebacterial opsin receptors
1

PTH, Parathyroid hormone receptor; 2 PTHrP, Parathyroid hormone related peptide

receptor; 3 GABAb, γ-Aminobutyric acid receptor
(Modified from Flower et al [4])

6

presence of a disulfide bridge between the first extracellular loop (EL1) and second
extracellular loop (Fig.1B). The most distinguishing characteristic of class B is that the
amino terminus contains several cysteines, presumably forming a network of disulfide
bridges [15]. The class C is relatively a smaller group, containing the metabotropic
glutamate and γ-amino-butyric acid receptors, the calcium receptors, the vomeronasal,
mammalian pheromone receptors, as well as some taste receptors [16]. All receptors in
class C have a very large extracellular amino terminus (500-600 amino acids) (Fig.1C)
that seems to be crucial for ligand binding and activation [17, 18]. Class D is the STE2
yeast pheromone receptors, and class E is the STE3 yeast pheromone receptors. These
two groups will be discussed in the next section (Chapter 2). Finally class F comprises
the receptors that are related to slime mold cyclic adenosine monophosphate (cAMP)
receptors and archaebacterial opsins.

The tertiary structure of GPCRs
Information about the tertiary structure of a GPCR is crucial for the understanding
of its function and for the design of drugs to correct possible problems caused by failure
of its function. Currently methods used to understand receptor structure and the
interactions of the ligand with its receptor at the atomic level include X-ray
crystallography, electron microscopy or diffraction, NMR spectroscopy and molecular
modeling. One of the advantages for NMR spectroscopy compared to the other methods
is that dynamic information can be obtained. However, structural information requires
high concentrations of dissolved pure protein. Except for several studies where single

7

helices were measured in a membrane, using solid state NMR, technical problems have
precluded NMR studies from yielding structural information on GPCRs [19].
Currently, five crystal structures of GPCRs have been revealed (Fig. 2). The first
crystal obtained was that rhodopsin resolved as a highly organized seven transmembrane
bundle with 11-cis-retinal, which is a key cofactor involved in maintaining rhodopsin in
the ground state [20]. An interesting feature is that some of the transmembrane helices in
rhodopsin are not regular α-helices [21]. The helices are bent around proline, one of the
strongest distortion is at Pro267 in TM6 (a highly conserved residue among GPCRs). It
has been shown that mutations at this residue cause conformational changes on
intracellular loop 3 [22]. In addition, a pronounced kink is observed in TM2, caused by
flexibility in the Gly-Gly sequence in the middle of this helix. The crystal structure also
revealed a short 8th helix, which runs parallel to the cytoplasmic membrane. This helix
and the generated fourth cytoplasmic loop cover part of the binding site for the Cterminus of Gtα subunit and play a role in Gtγ binding. A set of residues including the 8th
helix on the cytoplasmic surface, where G protein activation occurs, likely to undergo a
conformational change upon photoactivation of the chromophore that leads to G protein
activation and signal transduction [21].
Several years after the rhodopsin structure was published, Kobilka and colleagues
[23-25] published two different structures of the β2-adrenoceptor. Two initial structures
of β2AR were crystallized, one was fused with T4-lysozyme and another was bound with
antagonist. Also crystal structure of β2AR was crystallized in a complex with an anti
intracellular loop (IL) 3, Fab fragment, at 3.5Ǻ resolution. Both structures were similar
indicating that the T4 lysozyme fusion had little effect on the structural properties of the
8

Figure 1 Classification of human GPCRs
Class A GPCRs are characterized by several highly conserved amino acids in the TMs,
and there is usually a disulfide bridge linking extracellular loops 1 and 2. Most of the
class A receptors have a palmitoylated cysteine residue in the intracellular C-terminal tail.
The binding sites of the endogenous small-molecule hormone ligands of class A GPCRs
are located within the 7 TM bundle (A-1, the ligand binding site is indicated in orange).
For peptide and glycoprotein hormone receptors (A-2 and A-3, respectively), binding
occurs at the N terminus, the extracellular loop segments, and the extracellular parts of
the TM helices. Class B GPCRs contain a relatively long N-terminal tail (B). The class B
receptors show a number of conserved proline residues within the TMs. The majority of
class C receptors are characterized by very large N- and C-terminal tails, a disulfide
bridge connecting the first and second extracellular loops, together with a very short and
well-conserved third intracellular loop (C). A number of the strongly conserved residues
of class A GPCRs are also strongly conserved in class C GPCRs. The ligand binding site
is located in the N-terminal domain, which is composed of the so-called venus flytrap
(VFT) module that shares sequence similarity with bacterial periplasmic amino acid
binding proteins. In all class C GPCRs except the GABAB receptor, a cysteine-rich
domain (CRD), which contains nine conserved cysteine residues, links the VFT to the 7
TM domain (Modified from Jacoby et al [6]).

9

A-1

A-2

A-3

B

C
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antagonist bound receptor. Soon afterward, an additional structure of β2AR-T4-lysozyme,
which had a stabilizing point mutation, E122W, was solved in complex with the inverse
agonist timolol revealing a cholesterol-binding site [26, 27]. Then, the turkey β1AR
structure was solved in the presence of a strong antagonist cyanopindolo [28]. The overall
structure was very similar to that of human β2AR with the exception of the second
intracellular loop, a short helical segment in the turkey receptor whereas it was a random
coil in human β2AR. The adenosine A2a receptor structure was also solved in complex
with the antagonist ZM241385 [29]. The adenosine structure showed a shifted ligandbinding site and even greater helical shifts relative to rhodopsin and β2AR. Then, a major
breakthrough was made by Ernst and colleagues [30, 31]. They published the crystal
structure of light-activated opsin in complex with the C-terminal peptide corresponding
Gα subunit, transducin. Although the agonist was lacking in this structure, it may would
be considered to be an active state of GPCR because of the bound C-terminal Gα peptide
[32]. Importantly, the structure demonstrated significant deviation from the inactive form
of rhodopsin in the arrangement of the seven helical bundles.
Compared to the rhodopsin structure, each GPCR crystal structure had similarities
and differences [33, 34](Fig. 2). Sequence conservation among class A GPCRs is highest
within the transmembrane regions. Thus, it is not surprising that the helical bundle
orientation and packing is similar among the structures solved to date while the
extracellular region of the βARs is very open compared to rhodopsin. The most
prominent feature is a short helical segment within extracellular loop (EL) 2 that is
supported by limited interactions with EL1 and two disulfide bridges. The extracellular
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region of the adenosine receptor is highly constrained by four disulfide bridges and
multiple polar and van der Waals interactions among the three loops.
The position of the antagonist-binding pocket varies significantly as a function of
the receptor. The binding pocket of the β-adrenergic receptor is quite similar to that of
rhodopsin, while the ligand binding pocket seems to be very different in the A2a
adenosine structure. Based on sequence conservation and the initial bovine rhodopsin
structure, it was considered that the DRY motif at the intracellular base of TM3 found in
most class A GPCRs interact with a glutamate residue at the base of TM6. However,
looking at the structure of β2AR, β1AR, A2a, this is unlikely.

Ligand binding and receptor activation
GPCRs are activated upon binding of ligand which is varied, ranging in size from
small molecules to large glycoproteins. Many studies on receptor research are focused on
identification of the binding domains for ligands, using genetic, biochemical, and
biophysical approaches [13]. Site-directed or random mutagenesis of receptor, domain
swapping, and use of labeled probes are the most commonly used methods for
understanding structure-function relationship between GPCRs and their ligands. The
binding sites of endogenous “small-molecule” ligands in class A receptors, such as for
the retinal chromophore in rhodopsin and catecholamines in the adrenergic receptors are
the most widely studied and well characterized of these receptor-binding domains [35-37].
Recent studies on several peptide receptors such as the receptors for angiotensin [38-40],
parathyroid hormone [41, 42], secretin [43], bradykinin B2 [44, 45], gonadotropin12

releasing hormone [46], opioids [47, 48], neurokinin (NK) [49, 50], vasopressin/oxytosin
[51-53], cholecystokin/gastrin [54, 55], and neurotensin 1 [56] supplied valuable
information on the binding domains for other classes of GPCRs. Overall similarities are
observed among ligands, although there are specific and various interactions between
GPCRs and their cognate ligands. For example, large ligands, such as proteins, bind to
extracellular loops, while small molecules, including pharmacological agents, bind within
the transmembrane region of receptor (Fig. 1). On the other hand, peptides exhibit a
combined binding mode; they bind primarily to the extracellular loops while part of the
ligand may penetrate into transmembrane region and interacts with residues buried in
lipids [57-60].

Conformational Changes Involved in Agonist Induced GPCR Activation
For a long time, there was a simple model that receptors were depicted as bimodal
switches with inactive and active forms. However, a growing body of experimental
evidence provided information that GPCR is dynamic and has many different
conformations [61, 62]. This newer model for GPCR activation is called multi-state
model and suggests that the receptor alternate spontaneously between multiple active and
inactive conformations [63]. Various GPCRs, for example 5-HT2-serotonin receptors [64]
α2A-adrenoceptors [65], AT1 receptor [66], gonadotropin-releasing hormone receptors
[67], µ-opioid receptors [68] and many others, have been studied with respect to different
receptor conformations supporting the multi-state model. Today, it is commonly accepted
that different ligands can induce different receptor conformations [69] and this,
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Figure 2 Panel of Representative GPCRs Solved to Date
Each group of receptors is represented by one structure (same orientation). This figure
highlights the observed differences seen in the extracellular and intracellular domains as
well as the small differences seen in the ligand binding orientations. Light blue indicates
transmembrane domains, darker blue indicates intracellular regions, brown indicates
extracellular regions, orange indicates ligand. Yellow represents bound lipids and green
represents the conserved tryptophan residue. (Adapted from Hanson and Stevens [33])
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phenomenon has been described by several synonyms such as ‘functional selectivity',
‘agonist-directed trafficking' or ‘biased agonism'. Recently, it has been suggested that the
number of different terms be limited by using the term ‘functional selectivity’ or ‘ligandinduced differential signalling’ to describe this phenomenon [70].
The term ‘efficacy’ is used to describe the effect of ligand on the functional
properties of the receptor. Agonists are defined as ligands that fully activate the receptor.
‘Partial agonists’ induce submaximal activation of the G protein even at saturating
concentrations. ‘Inverse agonist’ inhibits basal activity. Antagonists have no effect on
basal activity, but competitively block the access of other ligands [70].

Intramolecualr interaction of TMs and TM movements during receptor activation
The non-covalent interactions between TMs have an important role in
determining the specific basal arrangement of the TM segments. For example, cotransfecting a plasmid encoding the amino terminus to TM5 of the β2 adrenoceptor
(β2AR) and a plasmid encoding TM6 to the carboxyl terminus of β2AR generates a
functional ‘split’ receptor [71]. Also, in the M3 muscarinic receptor system, a functional
receptor has been generated with discontinuity in the loop connecting TM3 and TM4, the
loop connecting TM4 and TM5, and the loop connecting TM5 and TM6 [72]. In addition,
analysis of the crystal structure of bovine rhodopsin suggests that the inactive state
conformation of rhodopsin is stabilized by multiple interhelical salt bridges and
hydrophobic interactions [73]. There is a Schiff base formation between Glu113 in TM3
and Lys296 in TM7 of bovine rhodopsin in the resting state. Single point mutations of
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Glu113 and Lys296 in bovine rhodopsin have been found to lead to constitutive receptor
activity [74, 75]. Site-directed mutagenesis experiments with bovine rhodopsin have
demonstrated that a mutation of Gly 90 to Asp 90 in TM2 can substitute for Schiff base
counterion Glu113 in TM3 [76].
Agonist binding is thought to alter the network of stabilizing intramolecular
interactions to favor an active conformation. Figure 3 shows two possible ways how
ligands might change intramolecular interactions and the arrangement of TM domains.
First, agonists may induce a conformational change by simply disrupting intramolecular
interactions (Fig. 3a), thus favoring new interactions that stabilize the molecule. Second,
agonists may serve as bridges to create new interactions between TM domains (Fig. 3b).
For example, catecholamines can interrupt the ionic lock of β2AR without interacting
with amino acids directly involved in the ionic lock [77].
In rhodopsin, it was reported that TM6 undergoes the largest movement upon receptor
activation and smaller changes were observed for TM3 [79]. Consistent with this,
movements of TM3 and TM6 during agonist-induced conformational changes have been
demonstrated in β-adrenoceptor [80, 81]. The angiotensin AT1 receptor also provides an
example that Asn111 interacts with Asn295 in TM7 in the inactive state [82], while
Asn111 seems to interact with Tyr4 in the active state [83]. Therefore, agonist binding
might disrupt the interaction between Asn111 and Asn295. Consistent with this
interpretation, mutation of Asn111 to alanine leads to constitutive activity [84]. M3
muscarinic receptor was also studied for intramolecular interactions. It was found that the
cytoplasmic end of TM6 of this receptor undergoes a rotational movement [85], and the
distance between the cytoplasmic ends of TM1 and TM7 was increased during activation.
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In contrast the extracellular ends of TM3 and TM7 move closer to each other upon
agonist stimulation [86, 87]. To gain information about the switch from an inactive
conformation to active receptor conformation(s), as a method for probing spatial
proximity of residues in TMs, several different techniques such as site-directed spin
labeling, sulfhydryl reactivity study, and fluorescence resonance energy transfer (FRET)
have been developed and used over the past decade. In addition, the disulfide crosslinking strategy has been applied to many GPCRs such as bovine rhodopsin [88-92], M3
muscarinic receptor [85, 87], and Ste2p [93]. For example, a disulfide bridge was built
successfully between Val204Cys in TM5 and Phe276Cys in TM6 of bovine rhodopsin
[89], which previously had been probed by metal ion site construction [94] and between
Val223Cys in TM5 and Leu247Cys in TM6 of Ste2p [93]. Whereas numerous
intramolecular constraints for inactive state conformations of GPCRs have been
identified, much less is known about the intramolecular interactions stabilizing the active
state conformations. The identification of intrahelical interactions will provide a
molecular basis for understanding mechanistic information relating to GPCR activation
pathways. In part II in this dissertation, the inter-helical interactions will be discussed in
more detail.
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Figure 3 Possible mechanisms how agonist binding disrupts intramolecular
interactions that stabilize the inactive state
(a) The agonist binds directly to amino acids involved in stabilizing the inactive state. (b)
Agonist binding stabilizes new intramolecular interactions. (Adapted from Kobilka and
Deupi [78])
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CHAPTER 2 α-factor pheromone and its G Protein-Coupled receptor
(Ste2p) in Saccharomyces cerevisiae
GPCRs in fungi
Since the glucose/sugar sensor in yeast, Gpr1, and homologs in other fungi are not
included in the classical classification of GPCR, recently new classification system for
fungal GPCRs have been proposed (Table 3). The GPCRs in fungi are categorized into
six classes; Ste2p-like pheromone receptor, Ste3p-like pheromone receptor, carbon/amino
acid receptor, putative nutrient receptor, cAMP receptor-like, and microbial opsin [95].
The pheromone sensing GPCRs in fungi are well studied and many pheromone
receptors have been identified based on conserved sequences and structures [95]. For
example, in A. nidulans, GprA and GprB were identified as pheromone receptors based
on sequence homology to Ste2 and Ste3 of S. cerevisiae [96]. In addition, it is surprising
that the pheromone receptors were found to be expressed constitutively even in species
which have no sexual cycle documented yet, such as Candida glabrata and Aspergillus
fumigatus [97-99]. The conserved MAPK cascade based on the model established in S.
cerevisiae has also been linked to morphogenesis and virulence in many fungal pathogens
such as the rice blast fungus M. grisea, and the human pathogens C. albicans and C
glabrata. [95].
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Table 3 Six classes of GPCRs in fungi
Species

Ste2-like
pheromone
receptor

Ste3-like
pheromone
receptor

Carbon
/amino
acid receptor

Putative
nutrient
receptor

Ste2

Ste3

Gpr1

Mam2

Map3

Git3

Ste2

Ste3

Gpr1

Aspergillus
nidulans

GprA

GprB

Aspergillus
fumigatus

Afu3g14330

Afu5g07880

GprC
GprD
GprE
Afu7g04800

Neurospora
crassa

Pre-2

Pre-1

Gpr-4

Magnaporthe
grisea
Basidiomycetes
Cryptococcus
neoformans
Ustilago
maydis
Coprinopsis
cinerea

MGG_04711

MGG_06452

MGG_08803

MGG_04698
MGG_02855

–

Ste3α/Ste3a
Cpr2
Pra1
Pra2
Rcb1
Rcb2
Rcb3
CC1G_
02129

Gpr4

Gpr2
Gpr3
UM06006
UM01546
CC1G_07132
CC1G_04180

Ascomycetes
Saccharomyc
es cerevisiae
Schizosaccha
romyces
pombe
Candida
albicans

–
–

–
–

cAMP
receptor-like

Microbial
Opsin

SCRG_01312
SCRG_02823
SCRG_00179
Stm1

–

–

–

–

CAWG_02899
CAWG_06059
CAWG_02686
GprF
GprG
AN5720
Afu5g04100
Afu1g06840
Afu1g11900
Gpr-5
Gpr-6

–

–

GprH
GprI
AN8262
Afu3g01750
Afu5g04140
Afu3g00780
Gpr-1
Gpr-2
Gpr-3
MGG_06738

AN3361

-, no homolog has been identified. (Modified from Xue et al [95])

20

Gpr4
Gpr5
UM03423
CC1G_02288
CC1G_02310

Afu7g01430
Nop-1
ORP-1
MGG_09015

CNAG_03572
(Ops1)
UM02629
UM04125
–

α-factor Pheromone and its G Protein-coupled receptor (Ste2p) in Saccharomyces
cerevisiae
One of the challenges in GPCR research is the complexity of eukaryotic systems,
due to the presence of receptor subtypes and cross-talk between different types of
receptors regulating many different pathways. S. cerevisiae is a species of budding yeast
which is most widely known as perhaps the most intensively studied eukaryotic model
organism in molecular and cell biology. The S. cerevisiae α-factor receptor system
has been used as an ideal system to understand GPCR structure-function as a model for
peptide hormones [100]. The power of yeast genetics has been used to examine the
structure –function relationship of α -factor receptor. The mitogen-activated protein
kinase (MAPK) system is simple but well conserved with higher eukaryotic systems. The
S. cerevisiae has only three GPCRs, two pheromone receptors (Ste2p and Ste3p) and the
Gpr1p which is a carbohydrate sensor. Although the pheromone and carbohydratesensing pathways share some down-stream components, there is no cross-talk between
the two systems as the pheromone receptors and the Gpr1p couple to two different Gproteins (Gpa1p and Gpa2p, respectively) [101, 102]. Thus S. cerevisiae provides an
ideal system to study the relation between a peptide ligand and its GPCR in the absence
of interfering biological complexities.
Mating in yeast, Saccharomyces cerevisiae
S. cerevisiae can exist as a haploid or diploid [103, 104]. Haploid cells have two
mating cell types MATa and MATα, distinguished by the expression of a set of genes
involved in mating that are not expressed in diploids. The secretion and reciprocal
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detection of peptide pheromones (α -factor and a-factor) by GPCRs (Ste2p and Ste3p,
respectively) initiate mating and eventual fusion of two haploids (Fig. 4) [100, 105]. The
mating pheromones are essential to trigger the mating cycle, therefore the cells that
cannot produce these molecules or lack their cognate receptors Ste2p or Ste3p become
sterile. The tridecapeptide α -factor pheromone WHWLQLKPGQPMY peptide was
chemically synthesized and found to exhibit all the properties of the natural pheromone
[106, 107]. The a-factor of S. cerevisiae is a dodecapeptide pheromone
(YIIKGVFWDPAC[Farnesyl]-OCH3) [108], and post-translational modification with a
farnesyl isoprenoid and carboxymethyl group is required for full biological activity of
this peptide [109].
Pheromone binding to its GPCR and activation of the βγ subunit of G protein
trigger the downstream MAPK cascade which activates the transcription of genes
involved in the production of pheromone itself, pheromone receptor and the proteins of
the signaling pathway (Fig. 5). The cells synthesize cell surface molecules necessary for
fusion with their mating partners, arrest in the G1 phase of the growth cycle by
eliminating the function of G1 cyclin complex and Cdc28 protein kinase to obtain
synchrony for mating, form mating projections that are involved in the fusion process,
thereby exhibiting a marked change in shape, and activate a number of genes that are
necessary for sexual conjugation [110, 111]. For long time, the Gα subunit Gpa1 was
known as a negative regulator. However, recently new evidence was reported that
pheromone signaling is also positively transmitted via Gpa1 [112]. Also it was suggested
that the GTP-bound form of Gpa1 can induce mating-specific transcription and
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morphogenesis in the absence of pheromone, via binding to the phosphatidylinositol-3kinase Vps34 [113].
The activation of cells by pheromone results in morphological changes. First,
conjugation projections are formed to facilitate connection of two opposite mating type
cells. By the action of agglutinins, the tips of the projections fuse forming a conjugation
bridge. Next, the nuclei migrate into the bridge and subsequently fuse to produce a
diploid nucleus of the zygote. All these morphological processes occur with an
involvement of cytoskeletal components, i.e., microtubules and actin structures, and the
cell wall [114]. Many of these cellular responses have been used to measure the activity
of this receptor and potency of pheromones and their analogs. Growth arrest (Halo) assay
and β-galactosidase activity assay generated by a FUS1-lacZ construct (the FUS1 gene is
transcriptionally activated by pheromone action) are the examples of methods based on
the cellular response.

Regulation of Ste2p in Saccharomyces cerevisiae and protein Signaling
Ste2p is highly regulated by several control mechanisms like many other GPCRs.
Among the general regulation mechanisms, three distinct processes contribute to α-factor
receptor regulation. These are (1) rapid phosphorylation and desensitization [115], (2)
internalization and recycling [115] and (3) down-regulation and degradation [116, 117].
The mating process in yeast is further regulated by the control of the expression levels or
the activities of the downstream elements in the signaling pathway
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MATα
MATa

Figure 4 Pheromone mediated mating in Saccharomyces cerevisiae
Schematic representation of pheromone/receptor mediated communication between
MATa and MATα haploid cells prior to mating.
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Figure 5 Saccharomyces cerevisiae mating pathway
Binding of pheromone to the receptor stimulates downstream responses such as
transcriptional activation of pheromone-induced genes, cell-cycle arrest, and polarization
of the cytoskeleton and growth components to the site of highest pheromone
concentration. Receptor activation not only triggers the mitogen-activated protein kinase
pathway (light modules) via G proteins (spotted modules), it also involves the receptor
carboxy-terminal domain. One model is that the carboxy-terminal domain, through direct
or indirect interaction (white circle) with the polarity-establishment complex (dark
modules), stimulates the repolarization of the actin cytoskeleton (speckled rectangle) to
the site of pheromone activation.
Ste5p, the scaffold protein; Ste20p, mitogen-activated protein kinase kinase kinase kinase
(MKKKK); Ste11p, MKKK; Ste7p, MKK; Fus3p and Kss1p, MAPK; Far1p, Cyclindependent kinase inhibitor; Ste12p, Transcription factor that is activated by a MAP
kinase signaling cascade; Bem1p, Protein containing SH3-domains involved in
establishing cell polarity and morphogenesis functions as a scaffold protein; Cdc42p,
Small rho-like GTPase; Cdc24p, Guanine nucleotide exchange factor (GEF or GDPrelease factor) for Cdc42p; Bni1p, Formin, nucleates the formation of linear actin
filaments; Fus1, gene encoding membrane protein localized to the shmoo tip and required
for cell fusion. (Modified from Madden and Snyder [114]).
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G proteins

Gα Gpa1p
Gβ Ste4p
Gγ Ste18p

e.g. Fus1
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(i.e. subunits of the G protein and/or MAPK). One of the well characterized regulators is
Sst2p, a yeast homologue of regulators of G protein signaling (RGS). RGS proteins are
important negative regulators of GPCR signaling. They function as GTPase-accelerating
proteins (GAPs) to inactivate Gα by increasing the hydrolysis rate of GTP bound Gα.
After GTP hydrolysis, the Gα subunit returns to its GDP-bound, then sequesters the Gβγ
complex into a heterotrimer, which lead to down regulation of G protein signaling. So far,
37 genes have been identified that encode proteins containing an RGS or RGS-like
domain within the human genome [118]. Sst2p is the first RGS protein identified in S.
cerevisiae. Recently it was found that Sst2p can directly bind to the C-terminal tail of
Ste2p via its DEP domain. In addition, binding to the receptor places Sst2p in close
proximity to Gpa1p, its substrate, implicating that regulation is both rapid and specific
[119].
Additionally, the phosphatases Msg5p and Mpt5p have been reported that have a
role in adaptive mechanism at higher concentrations of pheromone [120]. Expression of
some proteases like Bar1p (Sst1p), which specifically cleaves α-factor pheromone, adds
to the complexity of the regulation of mating [121].

Structure-function analysis of α-factor pheromone
The α-factor is a tridecapeptide secreted by MATα cells and has the sequence
WHWLQLKPGQPMY. Extensive analyses of α -factor analogs in combination with
receptor mutagenesis have provided insights into the structural basis of α-factor activity
[122-125]. Briefly, the results of these studies indicated that residues near the amine
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terminus play an important role in receptor activation, the carboxyl terminus of the
peptide contributes mostly to the binding affinity and the central residues of the peptide
forms a β-turn around the Pro8-Gly9 bond aiding the orientation of the signaling and the
binding domains of the pheromone (Fig. 6) [126-128]. A major experiment of this model
of α-factor activity was the systematic Ala substitute creating α-factor analogs have been
used to study the structure-function of the α-factor pheromone [129]. Several of the DAla series analogs, near the N-terminus, specifically [D-Ala2] α-factor, [D-Ala3] α-factor
and [D-Ala4] α-factor had no measurable biological activity [129]. However, these
peptides bound relatively strongly to Ste2p and antagonized the biological activity of
wild type ligand. These results were consistent with previous studies showing that
antagonists discovered involved changes in residues near the amine terminus indicating
that residues near this region are important for signaling. In contrast, the residues at the
carboxyl terminus of α-factor strongly affected to binding to Ste2p. Mutation of these
residues by either L- or D-Ala decreased affinity up to 3000-fold [129]. Removal of the
carboxyl terminal residues resulted in pheromones with significantly decreased receptor
affinity. Similar observations, separation of functional domains for binding and activity
have been reported for other peptide receptors [130-133].
The Pro-Gly sequence is located at the central region of α-factor, which has a
high probability of β-turns [134, 135]. It was suggested that a turn at this position was
involved in biological activity of the pheromone [136] and this region of the peptide may
create of the proper overall conformation for the pheromone [129]. Considering the
multi-state conformation of receptor, the separation of a binding domain and an
activation domain of α -factor suggests that there is a sequential binding of the
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pheromone to its receptor. The binding domain of α -factor may interact with the receptor
first, then binding of the remaining domains may occur in a sequential manner.
Consistent with this hypothesis, it was demonstrated that the fluorescent alpha-factor
analogue [K(7)(NBD), Nle(12)] bound to receptor via a two-step process involving an
initial interaction that places the fluorophore in a hydrophobic environment, followed by
a conversion to a state in which the fluorophore moves to a more polar environment [137].
One of the major goals of studies on GPCRs is understanding how ligands bind
to their receptor and how this information is transferred to activation of intracellular
pathway. Since yeast pheromones can be designed with chemically or photochemically
active groups that promote crosslinking to the receptor, the yeast α -factor pheromone
receptor was extensively used to study ligand binding. For example, a series of α-factor
analogs containing p-benzoyl-L-phenylalanine (Bpa), a photoactivatable group, were
synthesized [138]. Chemical and enzymatic fragmentation of the receptor/radio probe
complex ([Bpa1, Tyr3(125I), Arg7, Phe13]α-factor-crosslinked-Ste2p) indicated that
cross-linking occurred on a portion of Ste2p spanning residues 251-294 which covers a
portion of TM6, the extracellular loop between TM6 and TM7, and a portion of TM7
[138]. This was the first determination of a specific contact region between a Class D
GPCR and its ligand. Later, analogues of α-factor containing Bpa and biotin as a tag,
were synthesized to identify the pheromone binding site to receptor [139]. The study
using Bpa(1), Bpa(3), and Bpa(13) ligand suggested that the N-terminus of the
pheromone interacts with a binding domain consisting of residues from the extracellular
ends of TM5-TM7 and portions of EL2 and EL3 close to these TMs. It was also shown
that there is a direct interaction between the position 13 side chain and a region of Ste2p
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(F55-R58) at the extracellular end of TM1 in the same study [139]. In addition to the
mutagenesis studies, chimeric receptors between S. cerevisiae and S. kluyveri α-factor
receptors also supplied important information to understand the ligand receptor
interaction(s). A substitution at residues 47-49 of the the respective GPCRs affected
specificity for the respective pheromone binding but not for activation. In contrast,
substitution of residues 267-269 affected pheromone specificity for activation, but not for
pheromone binding. Finally substitution of residues 104-123 modestly affected both
types of specificity [140, 141]. Later, it was revealed that the side chain of the tenth
residue of α-factor is in close proximity with the side chains of residues 47 and/or 48 of
Ste2p when the pheromone is bound to the receptor [142]. Also, our group suggested that
portions of TM1 and TM6 were important for ligand interaction by using site-directed
mutagenesis of Ste2p and binding assays with different α -factor analogs [143]
Taking together, a model for α-factor bound to Ste2p was proposed (Fig. 7). The
model places α-factor bent around the Pro-Gly center of the peptide with the Lys side
chain facing away from the transmembrane domains and interacting with a binding
pocket formed by the extracellular loops. The side chain of Gln10 is proximal to residues
47 and 48 near the extracellular side of TM1, whereas the Trp1 side chain is near a
pocket formed by TM6-E3-TM7. Recently it was reported the Tyr13 side chain interacts
with Cys59 of Ste2p at the extracellular end of TM1 [144].
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Figure 6 Functional domains of α-factor ligand
Studies of α-factor analogs have revealed two regions according to their major
contributions to activity and binding affinity. The residues at the N-terminus appeared to
mainly function in activation of the receptor signaling, the residues at the C-terminus
strongly contribute to the binding affinity. However the two functions cannot be
completely separated. The loop domain corresponds to residues of the peptide which are
thought to induce a bend in the ligand structure. (Adapted from Abel et al [129])
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Figure 7 Working model for fitting of the α-factor pheromone into a ligand binding
site on its GPCR Ste2p
This schematic shows a counterclockwise orientation of TMs of the Ste2p. Two amino
acid residues (Ser 47 and Thr 48), were proposed that there are in the proximity to Gln10
of bound α-factor. The Tyr13 side chain of bound α-factor interacts with Cys 59 of Ste2p
at the extracellular end of TM1. The side chains of Trp1 and Trp3 bound α-factor interact
with the extracellular ends of TM5-TM7. The α-factor and the receptor extracellular
loops are represented by the gray curve and dotted lines, respectively. Contact residues
are denoted with stars with the residue number of the pheromone (Adapted from Son et al
[139]).
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CHAPTER 3 Oligomerization of GPCR
An overview
Protein-protein interactions are essential to the organizational structure and
function of cell signaling networks. Recently, a vast range of studies have been
documented that various classes of GPCRs form dimers and/or even higher order homooligomers [145-148]. Dimerization is thought to be important for various aspects of
GPCR function such as receptor biogenesis, formation of ligand-binding sites, signal
transduction, and down-regulation (Table 4). For example, the studies of DOP receptor
dimerization by Cvejic and Devi (1997) [149] provided evidence that the addition of
certain agonists would inhibit or reverse receptor dimerization. They concluded that the
DOP receptor was likely internalized from the cell surface as a monomer in response to
agonist challenge. It was reported that inhibition of dimer in β2-adrenoceptor by addition
of a synthetic peptide corresponding to TM6 of the receptor limit agonist activation of
adenylyl cyclase [150]. Thus, the study of dimerization has significance since
abnormalities of dimer formation may alter the function of the receptors which results in
serious disease. Indeed, many cases of dimerization is considered as a new drug targets
[6].
However, specifically for G protein activation and signaling, it is not resolved
whether a single GPCR molecule is sufficient or a dimer is necessary. Chabre and Maire
argued that all GPCRs appear to act as monomer based on a re-assesssment of previous
studies [151] while Park et al questioned the role and the existence of monomers in
nature [152]. It was reported that the monomeric NTS1 receptor activates Gq more
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Table 4 Proposed roles of GPCR dimerization/oligomerization

Role of dimerisation/oligomerisation

Receptor(s)

Protein folding

β2-adrenoceptor
CXCR11
α2-adrenoceptors
TSH2 receptor
Frizzled 4 receptor
Calcium sensing receptor
Melacortin-1 receptor

Efficient signal transduction

Rhodopsin
BLT13 leukotriene B4 receptor

1

CXCR, chemokine receptor; 2TSH, thyrotropin receptor; 3BLT2, leukotriene receptor;

(Modified from Milligan [147])
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efficiently than the receptor dimer in solubilized preparations [153] and monomeric
rhodopsin activates transducin as fast as the rate of protein diffusion allows in detergent
solution [22]. Also, rhodopsin monomers were found to activate transducin with the same
efficiency as two rhodopsins in the same particle where receptors were reconstituted into
lipid bilayer [154]. In contrast, it was reported that the higher-order rhodopsin oligomers
are the most active species for transducin activation by using functional analyses of
fractions from solubilized disk membranes [155].
Various transmembrane domains have been implicated to participate in receptor
oligomerization in different receptor systems (Table 5) suggesting that the structure of
oligomers formed in different GPCRs may not be the same [147]. Even within the same
receptor, homo-dimer formed by different monomer-monomer interaction from inactive
state to activate state [156]. The studies on class C receptors provide valuable information
that the N-terminal region may also participate into oligomerization as well as
transmembrane domains. The N-terminal Venus flytrap (VFT) module is one of main
characteristic for class C receptors, which is structurally and functionally homologous to
bacterial periplasmic proteins that bind amino acids, sugars and ions [157]. It was
reported that VFTs are important for dimerization of this receptor class [158, 159, and
160]. Additionally, it is known that cysteine-rich domains (CRDs), localized between
VFT and transmembrane domains, also have dimerization potential. It was demonstrated
that VFT–CRD modules form disulfide-linked dimers even when expressed without the
rest of the receptor from the mGlu1, mGlu4 and calcium-sensing (CaS) receptors [161163].
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Table 5 Structural domains reported to be involved in GPCR
dimerization/oligomerization

1

Receptor

Implicated domains

Rhodopsin

TM1 4, 5

Dopamine D2

TM 4

α1b-adrenoceptor

TM 1, 4, 5, 6

Complement C5a

TM 1, 2, 4

Adenosine A2a

TM 5

β2-adrenoceptor

TM 6

TM = transmembrane domain (Modified from Milligan [147])
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To directly examine the physical interaction between two GPCRs, differential
epitope tagging and selective immunoprecipitation have been valuable tools. Cysteine
cross linking has also used to detect dimers/oligomers. In addition, a variety of reagents
to cross-link two molecules have been employed [164, 165]. In order to address whether
GPCR dimers exist in living cells, biophysical techniques such as bioluminescence
resonance energy transfer, fluorescence resonance energy transfer have been employed to
visualize dimers/oligomers. In the part III of this dissertation, the cysteine cross-linking
method will be discussed in detail.

Dimer-/Oligomerization of Ste2p
Ste2p also can form a dimer. Two independent studies demonstrated that coexpression of an endocytosis-defective mutant with the wild-type receptor leads to
efficient internalization of the mutant receptor, suggesting that these receptors are
internalized as dimers [166, 167]. Overton and Blumer used fluorescence resonance
energy transfer (FRET) between differentially tagged receptors in whole cells as an
indicator for dimerization. They showed that tagged receptors lacking an endocytosis
signal were able to undergo endocytosis when co-expressed with wild-type receptor.
They also found the efficiencies of FRET were indistinguishable with agonist and
antagonist by dose-response and time-course experiments, thus Ste2p appeared to be
dimeric in the absence or presence of agonist. Using either whole cell or membrane
preparation yielded a similar FRET ratio [166, 167]. The study by Yesilaltay et al also
indicated that dimerized receptor complexes were subject to endocytosis and unoccupied
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receptors could also be internalized. In addition, they found that intermolecular disulfide
bonds between two intrinsic cysteines in Ste2p (C59 and C252) were unnecessary for
dimer formation [166, 167].
Overton and Blumer also used FRET to identify domains of Ste2p that mediated
dimerization and found TM1 was important for dimer formation. Various combinations
of receptor TM fragments were expressed with YFP or CFP taggs and FRET ratios were
measured. The major conclusion of the study was that TM1 has a significant role in
dimerization and is possibly involved help from the N-terminal extracellular domain and
TM2 to stabilize the dimer formation [168]. In a later study, it was also reported the
GXXXG motif in TM1 was involved in dimerization. Mutation of this motif of Ste2p did
not affect ligand binding but decreased cell signaling, indicating that dimerization is not
involved in ligand binding but is important for signal transduction [169].
It was also suggested that the dimer of Ste2p functioned in a concerted fashion.
Two different mutants, which were defective in promoting G protein activation were coexpressed and the ability to form a dimer in vivo and to correct their signaling were
measured, resulting in increasing signaling significantly [170]. Analysis of dominantnegative mutants of the receptor also suggests that dimerization may be important for
signal transduction. A dimer receptor formed between WT Ste2p and its dominant
negative mutant (Ste2p-Y266C) failed to signal, further supporting the idea that one role
for dimerization of Ste2p is efficient signaling [171].
Recently, receptors in other yeast species were found to have dimer forms that
may mediate important physiological functions of GPCRs in fungi. For example, the S.
pombe pheromone receptor Mam2 was found to form dimers during a study of a
39

constitutively active mutant [172]. In C. neoformans, domains of Gpr4 were shown to
interact with another Gpr4 in a yeast two hybrid system [173]. These studies suggest that
dimerization is a common phenomenon in fungi similar to GPCRs in other systems. In
the part III of this dissertation, identification of dimer interfaces of Ste2p will be
discussed in detail.
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PART II Study of Inter-Helical Interaction between
Transmembrane domain 1 and 7 of Ste2p
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CHAPTER 1 Abstract
The S. cerevisiae α-factor pheromone receptor, Ste2p, has been studied as a model
for G protein-coupled receptor (GPCR) structure and function. Today, it is widely
believed that receptors undergo conformational change(s) involving rearrangement of
transmembrane domains (TMs) upon ligand binding. In this study, 36 different
combinations of double Cys mutants were made by pairing six mutations on TM1 (L64 –
M69) with six on TM7 (L289 – M294). Although no inter-helical interactions were found
with the targeted residues under the experimental condition used, the results provided
strong evidence for Ste2p homo-dimerization.
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CHAPTER 2 Introduction

For about a decade from 1980 to 1990, the model for GPCR activation was
proposed to be a simple bimodal conversion between inactive and active states. However,
studies with various GPCRs, such as 5-HT2-serotonin receptors [1], α2A-adrenoceptors [2],
AT1 receptor [3], gonadotropin-releasing hormone receptors [4], and µ-opioid receptors
[5] showed that a receptor can exist in several different conformations, suggesting a
multi-state model. The multi-state model for GPCR activation proposes that the receptor
alternates spontaneously between multiple active and inactive conformations [6]. Today,
it is widely believed that different ligands can induce different receptor conformations [7].
Although the intracellular and extracellular loop regions play a role in receptor
activation, the non-covalent interactions between TMs seem to predominate for
determining the specific basal arrangement of the TM segments [8, 9, 10, 11, 12, 13] and
agonist binding is thought to change the inter-helical interaction between TMs potentially
leading to multiple receptor conformations. In the rhodopsin system, it was reported that
TM6 undergoes large movements upon receptor activation and smaller changes were
observed for TM3 [14]. Consistent with this, movements of TM3 and TM6 during
agonist-induced conformational changes have been demonstrated in the β-adrenoceptor
[15, 16]. The M3 muscarinic receptor is also used for studies of intramolecular
interactions. It was found that the cytoplasmic end of TM6 of this receptor undergoes a
rotational movement [17], and the distance between the cytoplasmic ends of TM1 and
TM7 was increased during activation. In contrast the extracellular ends of TM3 and TM7
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move closer to each other upon agonist binding in the M3 muscarinic receptor [18, 19].
As a method to detect interactions between residues in TMs, several different techniques,
such as site-directed spin labeling, sulfhydryl reactivity studies, and disulfide crosslinking strategies have been developed and used extensively [20-24].
In Ste2p, residues and regions in transmembrane domains involved in receptor
activation and signaling have been studied extensively [25-27]. For example, the studies
of dominant-negative mutations in the receptor indicate that most mutants exhibiting a
dominant-negative phenotype are located on the extracellular ends of the transmembrane
domains, especially TM5 and TM6 [28-30]. In addition, an interaction between
Val223Cys in the intracellular part of TM5 and L247C in the intracellular part of TM6 of
Ste2p has been identified by a cysteine-cross-linking experiment [25]. It was also
suggested that F204 in extracellular loop 2 was important for ligand binding and Y266 at
the extracellular end of TM6 was involved in signal transduction [31]. Consistent with
this, Yong et al revealed that N205 in TM5 is critical for signal transduction and interacts
with Y266 in a constitutively active receptor [32].
Whereas numerous intra-molecular restraints for the inactive state conformations
of GPCRs have been identified, little is known about the actual difference between the
inactive and active states at the molecular level. The identification of inter-helical
interactions specific to each state will provide a molecular basis for understanding
mechanistic information underlying GPCR activation pathways. To identify inter-helical
interactions between TM1 and TM7, we employed cysteine cross-linking. Although the
anticipated inter-helical interactions were not identified from this study, the results
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provided strong evidence for Ste2p dimerization which will be discussed in depth in
PART III of this dissertation.
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CHAPTER 3 Experimental procedures
Strains, Media, and Plasmids
Saccharomyces cerevisiae strain LM102 described by Sen and Marsh [33] was
used in the growth arrest and LacZ assays. The genotype for the LM102 strain is: MATa,
bar1, his4, leu2, trp1, met1, ura3, FUS1-lacZ::URA3, ste2-dl (deleted for the α-factor
receptor). The protease-deficient strain BJS21 (MATa, prc1-407 prb1-1122 pep4-3 leu2
trp1 ura3-52 ste2::KanR) was used in disulfide cross-linking and western blot assays to
decrease receptor degradation during analyses [34]. The parental plasmid, pHY4
expressing the template construct used for mutagenesis, FT-HT-Xa (cys-less Ste2p, the
FLAG and His epitope tags with Factor Xa cleavage cite) was generated by introducing a
tandem Factor Xa cleavage site between Val192 and Thr193 into pBec2 expressing FTHT (FLAG and His tagged Cys-less Ste2p) under a constitutive GPD promoter [35].
Twelve single Cys mutations ranging from Leu64 through Met69 on TM1 and Leu289
through Met294 on TM7 were generated in the pHY4 background by PCR based sitedirected mutagenesis [36]. The sequences of constructs were verified by DNA sequence
analysis completed by the Molecular Biology Resource Facility located on the campus of
the University of Tennessee. Primers were purchased from Sigma Genosys or IDT
(Coralville, IA). After sequence confirmation, constructs were transformed into the ste2deletion strains LM102 and BJS21 by the method of Gietz et al [37]. Transformants
bearing the pHY4 constructs were selected by their growth in the absence of tryptophan
on MLT medium (Medium lacking tryptophan) [38]. All media components were
obtained from Difco.
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Growth Arrest (Halo) Assay
Growth arrest was measured as described previously [32]. Briefly, filter disks
were impregnated with 10-µl portions of peptide solutions at various concentrations and
placed onto the overlay containing S. cerevisiae LM102 cells. The plates were incubated
at 30 °C for 24-36 h and then observed for clear zones (halos) around the disks. The halo
measured included the diameter of the disc. The normalized activity of each mutant was
determined by comparing halo size for the FT-HT-Xa receptor at 2µg of α-factor. All
assays were carried out at least three times with no more than a 2-mm variation in halo
size at a particular amount applied for α-factor.

FUS1-lacZ Gene Induction Assay
S. cerevisiae LM102 contains a FUS1-lacZ gene that is inducible by mating
pheromone. Cells were grown overnight in SD (synthetic defined) medium [Yeast
nitrogen base medium (Difco) without aminoacid] supplemented with the required amino
acids at 30 °C to 5 x 106 cells/ml, washed by centrifugation, and grown for one doubling
(hemocytometer count) at 30 °C. Induction was performed by adding 10-6 M of α-factor
to 1 ml of concentrated cells (1 x 107 cells/ml). The mixtures were vortexed and, after
incubation at 30 °C with shaking for 2 h, cells were harvested by centrifugation, and each
pellet was resuspended and assayed for β-galactosidase activity (expressed as Miller
units) in duplicate by using a β-galactosidase assay kit (Pierce) according to the
manufacturer's instructions. The activity of each mutant was normalized by comparing β-
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galactosidase activity for the wild-type strain. The standard deviation was determined
from three independent experiments.
Preparation of membranes
Membrane preparation of Ste2p was carried out essentially as described
previously [32]. Cells were grown to log phase, and then 1 x 108 cells were harvested by
centrifugation and lysed by agitation with glass beads in a lysis buffer containing 50 mM
Hepes, pH 7.5, 1 mM EDTA, 10 µg/ml phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin,
and 2 µg/ml pepstatin. The lysate was cleared by centrifugation at 2,000 x g for 5 min,
and then membranes were harvested by centrifugation at 15,000 x g for 45 min. The
membrane pellet was washed and then resuspended in 100 µl of a buffer (pH 7.4)
containing 10% glycerol, 50mM Hepes, 0.15mM NaCl, 2mM CaCl2, 5mM KCl, 5mM
MgCl2, 4mM EDTA [32]. The protein concentration was determined by the Lowry assay
(Pierce), and the membrane preparation was stored at -20 ºC overnight and used for
further assay the next day.

Disulfide Cross-linking with Cu-Phenanthroline
The 100 µg of membrane protein preparation was treated with a fresh preparation
of Cu(II)-1,10-phenanthroline (CuP; final concentration, 2.5 µM CuSO4 and 7.5µM
phenanthroline, pH 7.4). The treatment was carried out at room temperature for 30 min,
terminated with 50 mM EDTA and kept on ice for 20 min followed by adding Laemmli
sample buffer.
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Factor Xa digestion
The membrane protein preparation (40 µg) was incubated with 0.4 unit of Factor
Xa (Novagen) in Factor Xa cleavage buffer (0.1M NaCl, 50 mM Tris-HCl, 5 mM CaCl2,
pH 8.0) containing 0.1% Triton X-100 for 30min. Each sample was divided into two
aliquots. The reactions were terminated by adding one-third the volume of Laemmli
sample buffer (30% glycerol, 3% SDS, 0.01% bromphenol blue, 0.1875 M Tris, pH 6.8).
To one aliquot β-mercaptoethanol (final 1%, v/v) was added for reducing conditions.
Samples were analyzed by SDS-PAGE and Western blotting.

Western blot
Immunoblot analysis of Ste2p was carried out as described previously [32]. Each
sample was incubated at room temperature and then separated on NuPAGE 10% Bis-Tris
SDS-polyacrylamide gel (Invitrogen) using either non-reducing or reducing conditions
and electrophoretically transferred to ImmobilonTM-P membrane (Millipore Corp.,
Bedford, MA). The blot was probed with anti-FLAG M2 antibody (Eastman Kodak Co.)
or 1D4 antibody (a monoclonal antibody for rho-tag, purchased from Flintbox, BC,
Canada), and the bands were visualized with the West Pico chemiluminescent detection
system (Pierce).
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CHAPTER 4 Results
Expression and Biological Activities of Double Cys Mutant Receptors
To identify a possible inter-helical interaction between TM1 and TM7, 36
different combinations of double Cys mutants were made by pairing the six mutations on
TM1 with six on TM7. We chose twelve residues, six in TM1 (L64 – M69) and six in
TM7 (L289 – M294) proximal to the cytoplasmic face of Ste2p (Fig. 8A) for mutation to
Cys (Fig. 8A). These targeted residues were chosen for these reasons: (i) TM7 residues
mutated (L291 – M294) are highly conserved among fungal pheromone receptors [39],
(ii) TM1 and TM7 are in close proximity to one another in crystal structures of GPCRs
[40, 41] and a model of Ste2p [39]. To eliminate non-specific cross-linking the template
for these mutations was a Cys-less receptor. This template (FT-HT-Xa) also contained
two C-terminal epitope tags (FLAG and 6XHis) and tandem Factor Xa cleavage sites
(IEGRIEGR) in the second extracellular domain in order to facilitate detection of interdomain cross-linking (Fig. 8A). Native Ste2p, FT-HT (Cys-less Ste2p with the FLAG
and His epitope tags) and FT-HT-Xa (the template construct) receptors used in this study
demonstrated almost identical biological activities in a growth arrest assay indicating that
incorporating the protease site and the epitope tags did not alter receptor function (Fig.
8B).
The biological activities of the double Cys mutant receptors were measured and
the results were summarized in Table 6. Most double mutant receptors showed similar

71

Figure 8 A. The two-dimensional topology of Saccharomyces cerevisiae Ste2p and B.
Dose-response analysis of growth arrest assay
A.The cartoon indicates the location of the genetically engineered Factor Xa digestion
site in EL2 and the epitope tags in the C-terminus. The two endogenous Cys residues
(C59 and C252) were mutated to Ser to generate FT-HT-Xa which was the parental
plasmid used to generate the cysteine mutations in positions 64 to 69 in TM1 and 289 to
294 in TM7 as indicated in the boxes. The zone of growth inhibition of strains carrying
the indicated receptors was measured at various concentrations of α-factor. FT-HT-Xa is
the Cys-less receptor containing C-terminal FLAG and His epitope tags and a tandem
Factor Xa digestion site in EL2. FT-HT is the Cys-less receptor without the Xa digestion
site containing the FLAG and His epitopes, and Native Ste2p is the wild-type receptor
that has no epitope tags and has two Cys residues (C59 and C252).
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Table 6 Biological Activities of double Cys mutants

FT-HT-Xa
L64C L289C
T65C L289C
L66C L289C
I67C L289C
V68C L289C
M69C L289C
L64C P290C
T65C P290C
L66C P290C
I67C P290C
V68C P290C
M69C P290C
L64C L291C
T65C L291C
L66C L291C
I67C L291C
V68C L291C
M69C L291C
L64C S292C
T65C S292C
L66C S292C
I67C S292C
V68C S292C
M69C S292C
L64C S293C
T65C S293C
L66C S293C
I67C S293C
V68C S293C
M69C S293C
L64C M294C
T65C M294C
L66C M294C
I67C M294C
V68C M294C
M69C M294C
1

LacZ Activity
Basal1
Induced2
1.0 ± 0.08
1.0 ± 0.23
(3.7 unit)
(32 unit)
1.0 ± 0.13
1.0 ± 0.14
1.0 ± 0.09
0.8 ± 0.03
1.0 ± 0.09
0.8 ± 0.05
1.1 ± 0.13
0.7 ± 0.04
1.3 ± 0.16
0.8 ± 0.09
1.0 ± 0.08
0.8 ± 0.08
1.9 ± 0.16
1.0 ± 0.01
1.9 ± 0.11
1.0 ± 0.02
1.9 ± 0.15
0.9 ± 0.02
2.9 ± 0.15
0.9 ± 0.01
2.4 ± 0.27
1.0 ± 0.04
1.7 ± 0.17
0.8 ± 0.03
1.1 ± 0.04
1.7 ± 0.08
1.2 ± 0.02
0.5 ± 0.06
1.0 ± 0.01
1.0 ± 0.05
1.5 ± 0.05
1.4 ± 0.06
1.1 ± 0.03
0.5 ± 0.07
1.0 ± 0.08
1.0 ± 0.05
0.9 ± 0.09
1.0 ± 0.02
0.9 ± 0.08
1.0 ± 0.09
1.0 ± 0.12
1.4 ± 0.07
0.8 ± 0.03
1.1 ± 0.16
0.9 ± 0.05
0.9 ± 0.06
0.7 ± 0.01
1.0 ± 0.03
0.9 ± 0.03
1.0 ± 0.05
1.2 ± 0.03
1.1 ± 0.03
1.3 ± 0.03
1.1 ± 0.02
1.1 ± 0.05
1.0 ± 0.07
1.2 ± 0.05
1.2 ± 0.11
1.1 ± 0.02
2.1 ± 0.04
1.1 ± 0.04
1.1 ± 0.01
1.1 ± 0.05
1.3 ± 0.01
0.9 ± 0.03
1.1 ± 0.04
0.9 ± 0.02
1.0 ± 0.02
1.0 ± 0.08
0.5 ± 0.00
1.1 ± 0.06
0.5 ± 0.05

Halo Activity3
1
(24mm)
0.89
0.92
1.11
1.03
0.97
1.03
0.98
0.98
1.07
1.05
1.16
1.02
0.71
0.00
0.76
1.03
0.00
0.98
0.76
0.84
0.89
0.97
0.00
1.05
1.05
1.08
1.05
1.10
1.10
0.90
1.08
1.15
1.10
1.00
0.00
0.00

Relative activity (±standard deviation) compared with basal activity of FT-HT-Xa
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(Table 6 continued)
2

Relative activity (±standard deviation)compared with induced activity of FT-HT-Xa (α-

factor, 1µM)
3

Relative halo size compared with given halo size by FT-HT-Xa at 2 µg of α-factor. The

standard deviation of the halo activity for all receptors was within ± 0.2 (three replicates).
n.d. = not detected
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activity to FT-HT-Xa with the exception of five double mutant receptors (T65C/L291C,
V68C/L291C, V68C/S292C, V68C/M294C and M69C/M294C), which exhibited partial
activity as measured by the FUS1-lacZ assay. Moreover, the halo assay was used to
measure the long term effect of receptor activation [42, 43]. For example, it is possible
that conformational change introduced by specific mutations could alter coupling of the
receptor with G protein or influence endocytosis of the mutant receptor such that it
cannot efficiently arrest cell division.
The expression level of all double mutant receptors was similar to that of the FTHT-Xa receptor (Representative data, Fig. 9). The multiple bands on immubolots are
typical of Ste2p expression and are due probably to differences in the glycosylation state
receptor, which does not influence receptor function [44]. Taken together, we conclude
that Cys mutation of the targeted residues did not severely interfere with receptor
expression and function, with the specific exception of the five mutants (T65C/L291C,
V68C/L291C, V68C/S292C, V68C/M294C and M69C/M294C) indicated above.

Identification of Inter-molecular interaction between TMs using Factor Xa digestion
To identify inter-molecular interaction between TM1 and TM7, Factor Xa
digestion was used. The Factor Xa digestion site was engineered into EL2. Digestion
with Factor Xa cuts the intact receptor approximately in half. Therefore, if there is any
interaction between TM1 and TM7, the disulfide bond formed between the residues will
hold the receptor halves together following Factor Xa digestion (Fig. 10A) and a receptor
of intact size (55 kDa) would be detected by anti-FLAG antibody on an immunoblot of
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Figure 9 Expression of double Cys mutant receptors
Total membrane preparation from cells expressing each mutant receptor was analyzed by
SDS-PAGE. Receptor was detected by anti-FLAG antibody. The upper band (~110 kDa)
represents dimerized receptor and the lower band (~55 kDa) represents monomer.
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proteins run on a gel under non-reducing condition (Fig. 10B). Under reducing gel
conditions, this band would disappear and a smaller band corresponding to the C-terminal
half of the receptor would be detected by anti-epitope antibodies engineered into the Cterminus (Fig. 10A and B). Before each double Cys mutant was tested, various
parameters were examined to optimize the experimental conditions. Figure 11A shows
the optimal concentration of Factor Xa for receptor cutting is between 0.4 and 1.6 unit for
one hour incubation at 4 ºC. As expected, the C-terminal fragment of the receptor after
protease digestion was detected at approximately 33 kDa using anti-FLAG antibody (Fig.
11A). An anti-Ste2p antibody, which recognizes the first 100 amino acids of the receptor,
also successfully detected the N-terminal fragment of the receptor (22 kDa) following
digestion. Multiple bands around 22 kDa (Fig 11B) are due to differences in
glycosylation state as observed for the intact receptor.
All double Cys mutant receptors were analyzed by SDS-PAGE and western blot
after Factor Xa digestion. However, no intra-molecular interaction between TM1 and
TM7 was detected between the targeted residues. Instead, a band corresponding to a
66kD protein fragment (indicated by an arrow) was detected in double Cys mutant
combinations involving five TM7 residues (L289C, L291C, S292C, S293C and M294C)
(representative data for L291C and S293C shown in Fig. 12A and B). However, when an
additional Cys mutation was made at P290 with the same mutations of TM1, the 66 kDa
band was not generated (Fig. 12C). These data indicate that for specific residues in TM7,
mutation to cysteine supports the formation of TM7-TM7 dimers. Interestingly, this band
was detected only under non-reducing condition, and disappeared under reducing
conditions. The size of the this novel 66 kDa corresponds to a dimer formed from two
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fragments of C-terminal half of Ste2p joined by a disulfide bond, as would be expected to
occur following Factor Xa digestion of a TM7-TM7 dimer. The fact that this band was
not detected under reducing conditions supports the idea that this band was generated
from cysteine cross linking. To test this, Cu (II)-1,10-phenanthroline (Cu-P) was used to
treat all double Cys mutants to promote Cys-Cys disulfide bond formation. A protein
band around 110 kDa was expected if Ste2p formed dimers through the engineered Cys
residues in TM7. Indeed most of double cys mutants increased dimer population upon
Cu-P treatment. Double mutants expressing the P290C mutation did not show an increase
in dimerization, with the exception of I67C/P290C and V68C/P290C (Fig. 13). These
results strongly suggested that Ste2p forms homo-dimers through introduced cysteines
and led us to make single Cys mutants and further examine the capacity of these mutants
to form dimers. This will be discussed in Part III in detail.
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A. After Factor Xa digestion
Factor Xa

Cys

Cy s

Flag

B.

1

Cy
s

Cy s

Flag

33kDa

2

1

55kDa

2

Intact
Digested

Lane 1 No interaction
Lane 2 Interaction

Reducing
condition

Non-reducing
condition

Figure 10 2D diagram illustrated expected result for interaction
A. After Factor Xa digestion, around 33kD size of receptor fragment will be detected by
Anti-FLAG antibody in the absence of interaction and intact size of receptor will be
detected in the presence of interaction. B. Left panel describes expected result from nonreducing condition and right panel shows expected result from reducing condition.
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Figure 11 Factor Xa digestion of FT-HT-Xa
Total membrane was prepared from cells expressing FT-XT-Xa which is Cys-less
receptor tagged with FLAG/His containing tandem Factor Xa digestion sites in the
extracellular loop 2. A. Membrane was treated with different amount of Factor Xa as
indicated for an hour at 4°C. Samples were analyzed on SDS-PAGE and immunoblotted
with anti-FLAG antibody. B. Membrane was treated with different amount of Factor Xa
as indicated for 30 min at 4°C. Samples were analyzed on SDS-PAGE and
immunoblotted with anti-Ste2p antibody.
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Figure 12 Factor Xa digestions of double cysteine containing Ste2p receptors
Total membrane proteins derived from cells expressing indicated receptors were digested
with Factor Xa as described in the Methods. The digested samples were subjected to
SDS-PAGE under non-reducing (middle panel) or reducing conditions (right panel),
immunoblotted and probed by anti-FLAG antibody. Arrow indicates 66 kDa molecular
bands.
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Figure 13 Effect of Cu-P [Cu (II)-1, 10-phenanthroline] treatment on receptors
containing two cysteine replacements
Membranes were prepared, treated with Cu-P reagent, separated on SDS-PAGE. Each
sample was immunoblotted and probed with anti-FLAG antibody. The upper band (~110
kDa) represents dimerized receptor and the lower band (~55 kDa) represents monomer.
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CHAPTER 5 Discussion
We designed experiments to probe for inter-helical interactions between TM1 and
TM7 using Cys scanning mutagenesis and cross-linking. This method has been
extensively used to detect helical interactions in several GPCR systems [17, 23, 45-47].
Since our lab previously observed cysteine cross linking between N205C and Y266C
without the use of an oxidizing reagent [32], we also expected to identify any interactions
in TM1 and TM7 without using oxidizing reagents. However, no inter helical interactions
were found with the targeted residues under the experimental condition used. It is
possible that the intracellular parts of TM1 and TM7 in Ste2p are not close enough to
interact, or the side chains of the targeted residues are not in the optimal orientation to
form disulfide bonds, even though TM1 and TM7 are supposedly in close proximity
according to established models. In contrast, we found evidence for homo-dimerization
of Ste2p involving TM1 and/or TM7 which is discussed in detail in the next part of the
dissertation.
Interestingly, the expression level of the single Cys mutant P290C is very much
lower than for the FT-HT-Xa and Cys mutants at other positions (Fig. 15 in Part III).
However, double cys mutants with P290C showed better expression (Fig. 9). Even
though we could not detect any intra-molecular interaction between TM1 and TM7 with
the residues targeted in this study, the fact that adding another cysteine mutation on TM1
compensates for the expression defect of P290C indicates TM1 and TM7 may somehow
interact at the intra-molecular or inter-molecular level. In addition, double Cys mutant
containing P290C did not produce the 66 kDa band observed for the other double Cys
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mutants. This suggests that P290C may be important to maintain the proper conformation
of TM7 to allow for the formation of disulfide bonds between the surrounding TM7
residues (L289C, L291C, S292C, S293C and M294C). Taken together, the results
suggests that Pro 290 plays a critical role in receptor dimerization. Based on the results
which will be presented in part III of this dissertation, the region of TM7 we chose to
examine for potential interhelical interactions may not conform to the typical structure of
a transmembrane α-helix, as this portion of TM7 may be distended and flexible, making it
available for interaction with an adjacent receptor.
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CHAPTER 1 Abstract
The S. cerevisiae α-factor pheromone receptor, Ste2p, has been studied as a model
for G protein-coupled receptor (GPCR) structure and function. Dimerization has been
demonstrated for many GPCRs, although the role(s) of dimerization in receptor function
is disputed. Transmembrane domains one (TM1) and four (TM4) of Ste2p were shown
previously to play a role in dimerization. In this study, single cysteine substitutions were
introduced into a Cys-less Ste2p, and disulfide-mediated dimerization was assessed. Six
residues in TM1 (L64 to M69) that had not been previously investigated and nineteen
residues in TM7 (T278 to A296) of which fifteen were not previously investigated were
mutated to create 25 single Cys-containing Ste2p molecules. Ste2p mutants V68C in
TM1 and nine mutants in TM7 (cysteine substituted into residues 278, 285, 289, and 291
to 296) showed increased dimerization upon addition of an oxidizing agent in comparison
to the background dimers formed by the Cys-less receptor. The formation of dimers was
decreased for TM7 mutant receptors in the presence of α-factor indicating that ligand
binding resulted in a conformational change that influenced dimerization. The effect of
ligand on dimer formation suggests that dimers are formed in the resting state and the
activated state of the receptor by different TM interactions.
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CHAPTER 2 Introduction

G protein-coupled receptors (GPCRs) are membrane proteins that form one of the
largest and most diverse families of proteins in eukaryotes ranging from yeast to human.
Though the primary sequences are different among the GPCRs, all GPCRs share
common structural features: seven transmembrane helical domains (TMs) across the lipid
bilayer, with the TMs connected by intracellular and extracellular loops, an extracellular
N-terminus and an intracellular C-terminus [1]. GPCRs mediate responses to various
stimuli such as hormones, odors, peptides and neurotransmitters. Binding of ligand to a
GPCR triggers receptor-specific signals through a heterotrimeric G protein. Since it has
been reported that genetic variation of GPCRs often alters receptor functions such as
ligand binding, G protein coupling, and receptor life cycle, GPCR mutation is considered
a causative agent of many of human diseases [2]. GPCRs have been the most successful
molecular drug targets in clinical medicine [3].
Ste2p is the α-factor pheromone receptor in Saccharomyces cerevisiae and has
been used as a model for the study of the molecular basis of GPCR function [4-6]. Ste2p
can be replaced in yeast cells with mammalian receptors with functionality conserved [7],
and Ste2p can be expressed and trigger signal transduction upon ligand binding in
HEK293 cells [8]. Also, Ste2p can serve as an established model for fungal GPCRs.
Recently, many more GPCRs in fungi have been identified and classified into six
different categories based on sequence homology and ligand sensing [9]. Ste2p is the
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most well studied receptor among fungal GPCRs, some of which are suggested to be
related to fungal pathogenesis [9].
Recently, evidence has been growing that many GPCRs form homo- and/or
hetero- dimeric or oligomeric complexes [9-11]. Oligomerization has been discovered by
techniques such as crosslinking, bioluminescence resonance energy transfer, fluorescence
resonance energy transfer, and immunoprecipitation [10]. Dimerization is thought to be
important for various aspects of GPCR function such as receptor biogenesis, formation of
ligand-binding sites, signal transduction, and down-regulation [11, 12]. However, the
view that dimers are involved in the rhodopsin-like (Class 1A) receptor-activated
signaling has been challenged [13-16].
It has been demonstrated that Ste2p is internalized as a dimer/oligomer complex
[17, 18], and oligomerization-defective mutants can bind α-factor but signaling is
impaired [19]. It has also been shown that the dominant/negative effect on wild-type
signaling of a signaling-defective mutation in Ste2p (Ste2p-Y266C) can be partially
reversed by mutations in the G56XXXG60 dimerization motif, indicating that signal
transduction by oligomeric receptors requires an interaction between functional
monomers [20]. Recently, dimer interfaces were identified in Ste2p near the extracellular
end of TM1 and TM4 [21]. In that study it was found that dimerization was symmetric,
occurring between receptors at the TM1-TM1 interface or the TM4-TM4 interface. In our
current study, using the disulfide cross-linking methodology, we studied the participation
of specific residues at the intracellular boundary between TM1 and intracellular loop one
and the entire TM7 in Ste2p dimerization.
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CHAPTER 3 Experimental procedures

Strains, Media, and Plasmids
Saccharomyces cerevisiae strain LM102 described by Sen and Marsh [22] was
used in the growth arrest and LacZ assays. The genotype for the LM102 strain is: MATa,
bar1, his4, leu2, trp1, met1, ura3, FUS1-lacZ::URA3, ste2-dl (deleted for the α-factor
receptor). The protease-deficient strain BJS21 (MATa, prc1-407 prb1-1122 pep4-3 leu2
trp1 ura3-52 ste2::KanR) was used in disulfide cross-linking and western blot assays to
decrease receptor degradation during analyses [23]. The parental plasmid, pHY4
expressing the template construct used for mutagenesis, FT-HT-Xa (cys-less Ste2p with
the FLAG and His epitope tags with Factor Xa cleavage cite, see Table 7 for description
of the various receptor constructs used in this study) was generated by introducing a
tandem Factor Xa cleavage site between Val192 and Thr193 into pBec2 expressing FTHT (FLAG and His tagged Cys-less Ste2p) under a consititutive GPD promoter [24].
Twenty-five single Cys mutations ranging from Leu64 through Met69 on TM1 and Thr278
through Ala296 on TM7 were generated in the pHY4 background by PCR based sitedirected mutagenesis [25]. For co-expression experiments, plasmid pHY6 was
constructed from p426GPD, a 2-µm based shuttle vector with a GPD promoter, CYC1
terminator, and URA marker for selection in yeast [26]. STE2 containing C-terminal
FLAG and His epitope tags and a tandem Factor Xa digestion site in EL2 was PCRamplified from plasmid pHY4 using primers that introduced BamHI and EcoRI restriction
sites. The resulting PCR product was subcloned into the complementary sites of
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p426GPD. Also, to create pHY6 an epitope tag comprising codons encoding a 9-amino
acid sequence of rhodopsin (rho-tag) was substituted for the FLAG and His epitope tags
by ligation of a C-terminus part of STE2 product amplified from pBKY1[27]. Cys
mutants in this template were generated as described above. The sequences of constructs
were verified by DNA sequence analysis completed by the Molecular Biology Resource
Facility located on the campus of the University of Tennessee. Primers were purchased
from Sigma Genosys or IDT (Coralville, IA). After sequence confirmation, constructs
were transformed into the ste2-deletion strains LM102 and BJS21 by the method of Gietz
et al [28]. Transformants bearing the pHY4 or pHY6 constructs were selected by their
growth in the absence of tryptophan for pHY4 on MLT medium (Medium lacking
tryptophan) or in the absence of uracil for pHY6 on MLU medium (Medium lacking
uracil) [29]. All media components were obtained from Difco.

Growth Arrest (Halo) Assay
Growth arrest was measured as described previously [30]. Briefly, filter disks
were impregnated with 10-µl portions of peptide solutions at various concentrations and
placed onto the overlay containing S. cerevisiae LM102 cells. The plates were incubated
at 30 °C for 24-36 h and then observed for clear zones (halos) around the disks. The halo
measured included the diameter of the disc. The normalized activity of each mutant was
determined by comparing halo size for the FT-HT-Xa receptor at 2µg of α-factor. All
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Table 7 Receptors used in this study
Receptor name

Description

Wild-type

Native Ste2p

Ste2p-FT-HT

Wild-type with FLAG /His epitope tags

FT-HT

Cys-less Ste2p-FT-HT

FT-HT-Xa

FT-HT with tandem Factor Xa cleavage sites
Template for all Cys mutants generated in this study

Rho-Xa

Cys-less Ste2p with tandem Factor Xa cleavage sites and Rho tagged
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assays were carried out at least three times with no more than a 2-mm variation in halo
size at a particular amount applied for each peptide.

FUS1-lacZ Gene Induction Assay
S. cerevisiae LM102 contains a FUS1-lacZ gene that is inducible by mating
pheromone. Cells were grown overnight in SD (synthetic defined) medium (Yeast
nitrogen base medium (Difco) without aminoacid) supplemented with the required amino
acids at 30 °C to 5 x 106 cells/ml, washed by centrifugation, and grown for one doubling
(hemocytometer count) at 30 °C. Induction was performed by adding 10-6 M of α-factor
to 1 ml of concentrated cells (1 x 107 cells/ml). The mixtures were vortexed and, after
incubation at 30 °C with shaking for 2 h, cells were harvested by centrifugation, and each
pellet was resuspended and assayed for β-galactosidase activity (expressed as Miller
units) in duplicate by using a β-galactosidase assay kit (Pierce) according to the
manufacturer's instructions. The activity of each mutant was normalized by comparing βgalactosidase activity for the wild-type strain. The standard deviation was determined
from three independent experiments.

Preparation of membranes
Membrane preparation of Ste2p was carried out essentially as described
previously [30]. Cells were grown to log phase, and then 1 x 108 cells were harvested by
centrifugation and lysed by agitation with glass beads in a lysis buffer containing 50 mM
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Hepes, pH 7.5, 1 mM EDTA, 10 µg/ml phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin,
and 2 µg/ml pepstatin. The lysate was cleared by centrifugation at 2,000 x g for 5 min,
and then membranes were harvested by centrifugation at 15,000 x g for 45 min. The
membrane pellet was washed and then resuspended in 100 µl of a buffer (pH 7.4)
containing 10% glycerol, 50mM Hepes, 0.15mM NaCl, 2mM CaCl2, 5mM KCl, 5mM
MgCl2, 4mM EDTA [30]. The protein concentration was determined by the Lowry assay
(Pierce), and the membrane preparation was stored at -20 ºC overnight and used for
further assay the next day.

Disulfide Cross-linking with Cu-Phenanthroline
The 100 µg of membrane protein preparation were treated with a fresh preparation
(pH 7.4) of Cu (II)-1, 10-phenanthroline (Cu-P; final concentration, 2.5 µM CuSO4 and
7.5µM phenanthroline). The reaction was carried out at room temperature for 30 min,
terminated with 50 mM EDTA and kept on ice for 20 min followed by adding Laemmli
sample buffer. For study of the time course of cross-linking, Cu-P treated samples were
aliquoted at 45 sec, 2 min, 5 min, 10 min, 20 min, and 30 min before termination. In
experiments designed to prevent disulfide bond formation, the membranes were treated
with 5mM of NEM for 20min prior to incubation with Cu-P reagent. Alpha-factor or
antagonist [desW1,desH2]α-factor (10 µM final concentration) were added to the
membrane preparation and incubation allowed to proceed for 30 min prior to Cu-P
treatment in experiments performed to examine the influence of ligand on dimerization.
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Factor Xa digestion
The membrane protein preparation (40 µg) was incubated with 0.4 unit of Factor
Xa (Novagen) in Factor Xa cleavage buffer (0.1M NaCl, 50 mM Tris-HCl, 5 mM CaCl2,
pH 8.0) containing 0.1% Triton X-100 for 30min. Each sample was divided into two
aliquots. The reactions were terminated by adding one-third the volume of Laemmli
sample buffer (30% glycerol, 3% SDS, 0.01% bromphenol blue, 0.1875 M Tris, pH 6.8).
To one aliquot β-mercaptoethanol (final 1%, v/v) was added for reducing conditions.
Samples were analyzed by SDS-PAGE and Western blotting.

Saturation Binding assay with [3H]α-Factor
Tritiated α-factor (10.2 Ci/mmol) [31] was used in saturation binding assays on
total membrane preparations as described previously [29] Specific binding data were
analyzed by nonlinear regression analysis for single-site binding using Prism software
(GraphPad Software, San Diego, CA) to determine the Bmax value (receptors/cell) for each
mutant receptor. Each experiment was carried out at least 3 times. The close similarity
among three replicates is indicated by the standard deviations shown in Table 8.

Western blot
Immunoblot analysis of Ste2p was carried out as described previously [30]. Each
sample was incubated at room temperature and then separated on NuPAGE 10% Bis-Tris
SDS-polyacrylamide gel (Invitrogen) using either non-reducing or reducing conditions
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and electrophoretically transferred to ImmobilonTM-P membrane (Millipore Corp.,
Bedford, MA). The blot was probed with anti-FLAG M2 antibody (Eastman Kodak Co.)
or 1D4 antibody (a monoclonal antibody for rho-tag, purchased from Flintbox, BC,
Canada), and the bands were visualized with the West Pico chemiluminescent detection
system (Pierce). Blots were imaged, and the total density of all Ste2p bands in each lane
was determined using a ChemiDoc XRS photodocumentation system with Quantity One
one-dimensional analysis software (Bio-Rad). The intensity of the monomer and dimer
signal was measured by densitometry and the ratio of the signals was determined. The
percentage of dimer was calculated as [Dimer/(Dimer+Monomer) x100]. The averages of
the ratio were measured from at least three independent experiments and standard
deviations are presented in Table 9.

HIS-select HC Nickel affinity
Membrane preparations (500 µg protein) from each sample were resuspended in a
solubilization buffer (50 mM Tris HCl, 150 mM NaCl, 1% Triton X-100, 5 mM
imidazole, pH 8.0) overnight. The solubilized proteins were then mixed with HIS-select
HC Nickel affinity gel (Sigma) and incubated at 4OC for 30 minutes with end-over-end
mixing. The Nickel gel was separated from the mixture by centrifugation and then
washed five times with buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, 5 mM
imidazole). Ste2p was eluted from the Nickel gel two times using elution buffer (50 mM
sodium phosphate, pH 8.0, 0.3 M NaCl, 250 mM imidazole). The eluted samples were
analyzed by SDS-PAGE silver staining and western blotting using antibodies against
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FLAG, a 9-amino acid sequence of rhodopsin (rho-tag), or an antibody to the N-terminus
of Ste2p [32].

MTSEA Labeling
Membrane preparation was performed as decribed above. The 600 µg of the total
proteins in PBS buffer (1ml) were treated with MTSEA (2-[(biotinoyl)amino]ethyl
methanethiosulfonate) biotin in DMSO (0.1mM) for 2 minutes. Membranes were pelleted
by centrifugation at 15000 RPM for 5 minutes in cold room and resuspended in 600 µl of
RIPA buffer (0.1% SDS, 1% Triton X-100, 0.5% deoxycholic acid, 1 mm EDTA in 1×
PBS, pH 7.4), solubilized for 1 hour at 4 °C. After addition of 150 µl of streptavidin
slurry to the sample, it was incubated overnight at 4°C. The beads were then allowed to
settle by gravity and supernatant was removed. The pellet was washed with RIPA buffer
four times followed by washing with 2% SDS in PBS. The proteins were extracted from
the beads by incubating with 40 µl of Laemmli sample buffer at 55°C for 5 minutes. The
samples were separated on 10 % SDS PAGE. Westen blotting was performed and the
membrane blot was probed by using anti-FLAG as decribed. Labeling was expressed as a
percentage of accessibility for each individual mutant. Percent labeling was calculated by
quantitating total immunoreactivity of all bands on the FLAG immunoblot, then
normalized with T199C accessibility (=100%).
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CHAPTER 4 Results

Expression and Biological Activities of Cys Mutant Receptors
To begin the analysis of Ste2p dimerization we chose twelve residues, six in TM1
and six in TM7 (L289 – M294) proximal to the cytoplasmic face of Ste2p (Fig. 14A) for
mutation to Cys. To extend the initial cross-linking results, thirteen additional residues in
TM7 were mutated (T278C – S288C, W295C, and A296C) (Fig. 14A). These targeted
residues were chosen for several reasons: (i) The TM1 region chosen was one helix turn
away from the sequence G56XXXG60 previously established as being involved in Ste2p
dimerization [19], (ii) TM7 contains the AXXXA motif also suggested to play a role in
dimerization of other proteins [33] and 20 known growth factor receptors with tyrosine
kinase activity [34], (iii) eight of the TM7 residues mutated (S288-S293,W295 and A296)
are conserved among fungal pheromone receptors [35], and (iv) TM1 and TM7 are in
close proximity to one another in crystal structures of GPCRs [36, 37] and a model of
Ste2p [35]. To eliminate non-specific cross-linking the template for these mutations was
a Cys-less receptor. This template (FT-HT-Xa) also contained two C-terminal epitope
tags (FLAG and 6XHis) and tandem Factor Xa cleavage sites (IEGRIEGR) in the second
extracellular domain in order to facilitate detection of inter-domain cross-linking (Fig.
14A). Wild-type, FT-HT (Cys-less Ste2p with the FLAG and His epitope tags) and FTHT-Xa (the template construct) receptors used in this study demonstrated almost identical
biological activities in a growth arrest assay indicating that incorporating the protease site
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and the epitope tags did not alter receptor function (Fig. 8B in Part II). In addition, FTHT-Xa and Ste2p-FT-HT showed identical expression (Fig. 14B).
The expression level of each single-Cys mutant receptor was determined by
western blot analysis. All mutants except P290C showed several bands between 44kDa
and 55kDa and expression levels similar to that of FT-HT-Xa (Fig. 15A and Fig. 18A).
The multiple bands are typical of Ste2p expression and are due to differences in its
glycosylation state, which does not influence receptor function [38]. Although two
intrinsic Cys residues have been substituted, a weak band at 110 kDa, corresponding to a
dimerized form of Ste2p, was observed for the FT-HT receptor (Fig. 15B). This band is
likely a native, non-covalent dimer which was not disrupted by membrane protein
preparation or SDS-PAGE. Such dimers have been observed on SDS-PAGE gels by other
investigators working with Ste2p [20, 39, 40] and are also seen with the FT-HT-Xa
receptor (Fig. 20A; Lane 1). This weak dimer observed in the Cys-less receptor is
consistent with immunoprecipition results showing that the two intrinsic Cys are not
involved in dimerization [18].
Membrane expression of P290C receptor was very low when judged by western
blot (Fig.15A). It is known that one of the roles of the conserved proline in TM7 in
GPCRs is correct folding [41]. The reduced expression of P290C was observed
previously when it was shown that this receptor was primarily defective in plasma
membrane localization using a P290C-GFP receptor, but the P290C-GFP construct did
not demonstrate a defect in signaling [42].
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Figure 14 The two-dimensional topology of Saccharomyces cerevisiae Ste2p
A.The cartoon indicates the location of the genetically engineered Factor Xa digestion
site in EL2 and the epitope tags in the C-terminus. The two endogenous Cys residues
(C59 and C252) were mutated to Ser to generate FT-HT-Xa which was the parental
GPCR used to generate the TM1 and TM7 cysteine mutations in positions 64 to 69 in
TM1 and 278 to 296 in TM7 as indicated in the boxes. B. Expression of FT-HT-Xa.
Membrane proteins were analyzed by SDS-PAGE, then immunoblotted and probed with
anti-FLAG antibody
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Figure 15 Effect of Cu-P (Cu (II)-1, 10-phenanthroline) treatment on the
dimerization of Ste2p containing single cysteine mutations
Membrane proteins were treated with Cu-P or left untreated, followed by SDS-PAGE,
then immunoblotted and probed with anti-FLAG antibody. The upper band (~110 kDa)
represents dimerized receptor and the lower band (~55 kDa) represents monomer. A.
Receptors with Cys in TM1 or TM7 were treated with Cu-P (Right panel) or were
untreated (Left Panel). Receptors indicated in bold exhibited a shift in signal from
monomeric to dimeric form. B. Controls with Cys-less Ste2p-FT-HT and Ste2p-FT-HT.
C. V68C and S292C receptors were untreated or treated with Cu-P in the presence or
absence of NEM (N-ethylmaleimide) added prior to Cu-P treatment. D. Each indicated
receptors were treated with Cu-P in the presence of NEM (N-ethylmaleimide) added prior
to Cu-P treatment.
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Biological activity of each mutant was measured by growth arrest, β-galactosidase
activity and binding assays and is normalized relative to the parent receptor (Table 8).
Most mutant receptors showed similar β-galactosidase activity and growth arrest activity
as compared to FT-HT-Xa. Two mutants (M69C and L283C) showed slightly lower
induced β-galactosidase activities and A281C did not show growth arrest activity which
is consistent with a previous study [43]. The difference between β-galactosidase activity
and cell division arrest has been observed in many mutagenic studies of Ste2p [44-46]. It
has been proposed that a short term signaling effect is measured by the β-galactosidase
assay, whereas the long term effect is measured by the halo assay.
The α-factor binding affinities of most Cys mutants were the same and within the
experimental error range ( ± 2.5 fold), with the exceptions of the S292C, receptor which
showed an increase in binding affinity (5 fold lower Kd value), and the L283C and
S288C which showed a decrease in binding affinity (up to 4.7 fold higher Kd values) as
compared to that of FT-HT-Xa. B-Max values determined by a saturation binding assay
indicated that the numbers of binding sites were similar to FT-HT-Xa for most mutant
receptors, with the exceptions of T279C V280C, A281C and T282C, which showed
expression about 50% lower than that of FT-HT-Xa. The P290C receptor showed no
detectable α-factor binding, consistent with lack of measureable expression in the western
blot analysis. Nonetheless, this receptor exhibited comparable growth arrest and βgalactosidase activities, suggesting that there were sufficient receptors expressed on the
cell surface to elicit these biological responses upon ligand treatment (Table 8), albeit
below detectable levels as measured by binding or western blots. Previous studies have

111

Table 8 Biological activities of Cys mutant receptors
β-galactosidase Activity
Receptor

Growth
Arrest
activity3

Binding Assay4
B-Max

Kd(nM)

Basal
Activity1

Induced
Activity2

FT-HT-Xa

1.0 ± 0.1

1.0 ± 0.1

1.00

1.0 ± 0.3

1.0 ± 0.3

TM1

L64C

1.0 ± 0.1

0.9 ± 0.2

1.00

1.7 ± 0.2

2.5 ± 0.7

T65C

0.9 ± 0.1

0.9 ± 0.1

1.08

1.2 ± 0.2

1.5 ± 0.7

L66C

1.0 ± 0.1

1.3 ± 0.5

1.00

0.5 ± 0.1

0.5 ± 0.2

I67C

1.0 ± 0.1

1.1 ± 0.3

1.04

1.5 ± 0.1

2.2 ± 0.5

V68C

1.0 ± 0.1

0.9 ± 0.3

1.00

0.9 ± 0.2

1.1 ± 0.4

M69C

1.1 ± 0.1

0.7 ± 0.2

1.00

0.7 ± 0.1

1.0 ± 0.4

T278C

0.7 ± 0.1

0.9 ± 0.2

0.88

0.7 ± 0.1

0.7 ± 0.3

T279C

1.1 ± 0.2

0.9 ± 0.1

1.08

0.4 ± 0.1

0.4 ± 0.1

V280C

0.8 ± 0.1

1.3 ± 0.5

1.00

0.3 ± 0.1

0.5 ± 0.1

A281C

0.5 ± 0.1

1.1 ± 0.3

n.d

0.4 ± 0.1

0.8 ± 0.2

T282C

1.8 ± 0.5

0.9 ± 0.3

1.00

0.4 ± 0.1

0.9 ± 0.2

L283C

1.6 ± 0.3

0.7 ± 0.2

0.96

1.7 ± 0.7

4.7 ± 1.3

L284C

1.0 ± 0.1

0.8 ± 0.2

0.92

0.6 ± 0.1

1.1 ± 0.3

A285C

1.4 ± 0.1

1.0 ± 0.1

0.88

0.7 ± 0.2

0.9 ± 0.2

V286C

1.3 ± 0.1

1.0 ± 0.3

1.12

0.7 ± 0.1

1.9 ± 0.7

L287C

1.7 ± 0.1

1.0 ± 0.3

1.01

0.8 ± 0.1

1.1 ± 0.1

S288C

1.1 ± 0.1

1.0 ± 0.3

1.00

0.7 ± 0.1

4.1 ± 1.5

L289C

1.4 ± 0.1

0.8 ± 0.2

0.92

1.3 ± 0.2

2.1 ± 0.6

TM7
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(Table 8 continued)
P290C

1.4 ± 0.1

1.0 ± 0.1

0.88

n.d.

n.d.

L291C

1.3 ± 0.1

1.0 ± 0.3

0.88

0.6 ± 0.1

1.7 ± 0.8

S292C

1.4 ± 0.1

1.0 ± 0.3

1.04

0.6 ± 0.1

0.2 ± 0.1

S293C

1.5 ± 0.1

1.0 ± 0.3

1.00

1.2 ± 0.1

2.5 ± 0.4

M294C 1.2 ± 0.1

1.2 ± 0.4

0.94

0.8 ± 0.1

0.9 ± 0.2

W295C

1.7 ± 0.3

1.5 ± 0.3

1.01

1.3 ± 0.1

1.3 ± 0.1

A296C

1.7 ± 0.4

2.5 ± 0.8

1.00

0.7 ± 0.1

0.4 ± 1.5

1

Relative activity (±standard deviation) compared with basal activity of FT-HT-Xa
(Miller unit of FT-HT-Xa was 3.9)
2

Relative activity (±standard deviation) compared with induced activity of FT-HT-Xa
at 1µM of α-factor (Miller unit of FT-HT-Xa was 31.7)
3

The relative halo size (growth arrest) was compared to the halo size of the FT-HT-Xa
receptor at 2µg of α-factor applied to a disc (the halo size of FT-HT-Xa was 24 mm). The
standard deviation of the halo activity for all receptors was within ± 0.2 (three replicates).
n.d. = not detected
4

The Bmax and Kd values are presented relative to those of the FT-HT-Xa receptor.
The Bmax and the Kd were determined by saturation binding of radioactive α-factor
according to the protocol in Methods. n.d. = not detected, as the binding was not greater
than background (B-Max of FT-HT-Xa was 3491 and Kd was 10.7nM).
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shown that remarkably low levels of Ste2p at the cell surface are sufficient to manifest
the biological responses [47]. Taken together, we conclude that Cys mutation of the
targeted residues did not severely interfere with receptor expression and function. We did
not use the P290C receptor further in this study as it was expressed at a very low level.

Dimerization of Some Cys Mutants in TM1 and TM7 Is Markedly Enhanced by the
Oxidizing Reagent Cu (II)-1, 10-Phenanthroline
Initially we tested the involvement of twelve TM residues, six on TM1 and six on
TM7 (L289 – M294) proximal to the cytoplasmic face of Ste2p (Fig. 14), in dimerization.
As stated above, FT-HT-Xa and virtually all of the single Cys containing Ste2p mutants
exhibited weak bands at about 110 kDa consistent with a small amount of dimerized
Ste2p. However, in all cases the predominant band was near 55 kDa, the molecular mass
of monomeric Ste2p. When these same receptors were treated with Cu (II)-1, 10phenanthroline (Cu-P), a reagent that has been used as an oxidizing reagent to drive
disulfide bond formation in membrane proteins [48-51], many of the Cys mutated
receptors showed marked increases in the 110 kDa band and a concomitant decrease in
the monomer band (Fig 15A, Table 9). Notably, V68C, a TM1 mutant and five mutants
on TM7 (L289C, L291C, S292C, S293C and M294C) showed strong (>60%)
dimerization upon Cu-P treatment (Fig. 15A, Table 9). When FT-HT (epitope tagged
Cys-less receptor) and Ste2p-FT-HT (epitope tagged receptor with intrinsic cysteine
residues at C59 in TM1 and C252 in TM5) receptors were tested, there was no difference
in dimerization in the presence and absence of Cu-P treatment (Fig. 15B) indicating that
increased dimerization of mutant receptors was due to the specific cysteine residues
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Table 9 Effect of ligand binding on Cu-P (Cu (II)-1, 10-phenanthroline) stimulated
disulfide bond formation1
No treatment

Cu –P2

α, Cu-P3

A, Cu-P4

FT-HT-Xa

15.0 ± 4.4

12.0 ± 0.1

13.1 ± 0.2

12.2 ± 0.1

TM1 L64C

15.8 ± 0.1

11.3 ± 0.4

14.6 ± 1.0

13.6 ± 0.8

T65C

16.2 ± 0.1

14.4 ± 0.1

15.9 ± 0.3

12.8 ± 0.3

L66C

12.3 ± 0.4

11.9 ± 1.0

13.2 ± 0.4

11.9 ± 0.8

I67C

19.3 ± 4.5

17.0 ± 0.1

17.4 ± 4.1

18.0 ± 2.0

V68C

28.5 ± 3.2

99.2 ± 0.1

98.3 ± 0.8

98.8 ± 0.1

M69C

17.7 ± 6.9

14.2 ± 5.0

17.0 ± 6.4

28.9 ± 10.2

TM7 T278C

15.1 ± 0.8

65.8 ± 8.8

12.5 ± 0.1

12.4 ±0.1

T279C

17.3 ± 0.3

10.1 ± 2.3

15.8 ± 0.2

10.9 ± 2.7

V280C

15.3± 2.1

14.7± 1.5

16.3 ± 0.6

12.4 ± 0.1

A281C

16.8± 0.5

11.9± 0.6

14.3 ± 1.5

11.3 ± 0.1

T282C

11.7± 0.3

15.4± 0.1

12.0 ± 0.8

11.7 ± 0.1

L283C

16.6± 0.4

15.7± 0.2

13.3 ± 0.1

10.7± 3.5

L284C

15.2± 0.1

12.0 ± 0.2

17.7 ± 3.0

15.3 ± 0.1

A285C

16.5 ± 0.8

53.5 ± 8.3

16.5 ± 2.1

17.7 ±0.5

V286C

15.6 ± 0.4

17.0 ± 0.3

13.2 ± 2.0

15.9 ±0.4

L287C

16.0 ± 0.1

14.3 ± 1.3

11.3 ± 1.7

16.0 ±1.8

S288C

14.7 ± 1.0

14.7 ± 1.5

11.5 ± 0.6

12.6 ±0.2

L289C

26.8 ± 2.0

61.0 ± 9.8

50.2 ± 12.9

40.9 ±8.2

L291C

31.8 ± 0.4

66.4 ± 0.1

52.0 ± 8.8

44.5 ± 5.6

S292C

30.2 ± 8.3

82.3 ± 0.4

75.5 ± 11.4

65.9 ±0.2

S293C

21.1 ± 0.7

70.2 ± 5.3

38.5 ± 8.3

44.0 ±0.1

Receptor
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(Table 9 continued)
M294C

27.0 ± 7.6

75.6 ± 1.0

57.8 ± 0.7

50.8 ± 1.0

W295C

15.7 ± 0.2

95.2 ± 0.7

76.2 ± 0.6

86.3 ±0.1

A296C

14.8 ± 2.1

91.1 ± 1.0

73.6 ± 1.5

82.1 ±0.8

1

The intensity of the monomer and dimer signal was measured by densitometry and the
ratio of the signals was determined. The intensity of the monomer and dimer signal was
measured by densitometry and the ratio of the signals was determined. The percentage of
dimer was calculated as [Dimer/(Dimer+Monomer) x100].
2

Cu-P = Cu-P (Cu (II)-1, 10-phenanthroline) treatment.

3

α, Cu-P = membranes treated with alpha-factor and Cu-P(Cu (II)-1, 10phenanthroline).
4

A, Cu-P = membranes treated with antagonist and Cu-P(Cu (II)-1, 10-phenanthroline).
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engineered into Ste2p. To further test whether dimerization was mediated by disulfide
bond formation involving cysteine residues, NEM (N-ethylmaleimide) pre-treatment was
used. NEM alkylates the free –SH group of cysteine irreversibly, so that disulfide bond
formation cannot occur after NEM treatment. As shown in Figure 15C and D,
pretreatment of receptors, which increased dimer upon Cu-P, with NEM completely,
eliminated the Cu-P mediated dimerization (Fig. 15C, and D). In addition, in all cases
where a high level of crosslinking was observed the membranes were treated with Cu-P
and the reaction terminated by EDTA only and by EDTA and NEM to prevent
crosslinking that might occur upon subsequent manipulation of the sample. No
differences were found in the extent of crosslinking with the additional NEM treatment
(Table 10). In contrast to these six residues, placement of cysteine at positions 64, 65, 66,
67 and 69 followed by Cu-P treatment did not result in a dimer population that exceeded
20% (Fig. 15A, right panel). Taken together, the results indicate that insertion of cysteine
residues at position 68 on TM1 and positions 289, 291, 292, 293 or 294 on TM7 led to
high levels of Ste2p dimerization through disulfide formation.
Although the studies described above provided evidence for Cu-P catalyzed Ste2p
dimerization, it was possible that the single Cys mutant Ste2p is cross-linking with other
proteins with similar molecular weight to yield the observed high molecular weight bands.
To confirm that the observed dimer band in the western blot was a Ste2p-Ste2p homodimer, we took advantage of the protease (Factor Xa) digestion site engineered into EL2
of Ste2p. Cross-linking between two Cys residues in TM7 followed by Factor Xa
digestion would yield a homodimeric complex of 66 kDa (Fig. 16A). Indeed TM7
mutants (L289C, L291C, S292C, S293C and M294C) digested with Factor Xa led to
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Table 10 Effect of NEM on Cu-P(Cu (II)-1, 10-phenanthroline) stimulated disulfide
bond formation1
No treatment

EDTA2

EDTA and NEM3

16 ± 2.3

17 ± 2.3

16 ± 0.1

TM1 V68C

22 ± 10.3

99 ± 0.3

99± 0.1

TM7 T278C

22 ± 13.5

61 ± 1.7

54 ± 0.3

A285C

15 ± 4.5

58 ± 0.6

54 ± 0.2

L289C

11 ± 5.0

59± 2.5

53 ± 0.9

L291C

26 ± 8.8

64 ± 3.5

57 ± 0.1

S292C

17 ± 3.2

76 ± 0.8

70 ± 6.5

S293C

19 ± 5.5

75 ± 4.8

69 ± 4.8

M294C

26 ± 1.1

72 ± 6.3

76 ± 3.7

W295C

32 ± 8.3

80 ± 4.2

81 ± 3.5

A296C

39 ± 0.9

66 ± 8.3

79 ± 5.2

Receptor
FT-HT-Xa

1

The intensity of the monomer and dimer signal was measured by densitometry and the
ratio of the signals was determined. The percentage of dimer was calculated as
Dimer/(Dimer+Monomer) *100.
2

Sample was treated with Cu-P(Cu (II)-1, 10-phenanthroline) and the reaction was
terminated by EDTA only
3

Sample was treated with Cu-P(Cu (II)-1, 10-phenanthroline) and the reaction was
terminated by EDTA and NEM
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the appearance of a band near 66 kDa when SDS-PAGE was run under non-reducing
conditions (Fig. 16B; left panel). This band was markedly reduced when the gel was run
in the presence of β-mercaptoethanol, a potent disulfide reducing agent. The 66 kDa band
was specific for dimerized receptors with a disulfide connection between monomers as
the band was not observed for FT-HT-Xa (Cys-less) and a TM1 mutant (M69C) in which
there was no disulfide-mediated dimer formation (Fig. 16B). The monomer bands (~55
kDa) are due to an incomplete Factor Xa digestion. We performed partial digestion
because a longer incubation led to the degradation of all bands. Bands at ~33 kD are
Factor Xa digestion products of the monomeric receptor species (remaining in the
samples). The generation of this band from the S292C and S293C mutant receptors, in
which the majority of receptors formed dimers (Fig. 15A, right panel), is likely the result
of detergent induced (Triton X-100 in Factor Xa digestion buffer) dissociation of
background dimers. Indeed, the presence of background dimers from all the receptors
tested including FT-HT-Xa (Cys-less) and M69C were reduced in the presence of Triton
X-100.
Further support for the disulfide bond induced dimer formation was provided
when differentially tagged receptors were co-expressed. M294C mutants and FT-XT-Xa
were chosen for this experiment. Membranes from cells co-expressing receptors tagged
with the FLAG/His epitopes and receptors tagged with the Rho epitope were precipitated
using the HIS-select HC Nickel affinity column and immunoblotted with anti-Ste2p
antibody and anti-Rho antibody. The total amount of receptors present following immune
precipitation was determined using an antibody directed against the N-terminus of the
receptor (left panel, Fig. 17). For both the FT-HT-Xa/Rho-Xa and M294C/M294C-Rho
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receptors, bands corresponding to monomeric and dimeric forms were detected in both
the presence and absence of Cu-P treatment. The dimerized form was more abundant than
the monomer for the M294C/M294C-Rho receptor due to the presence of the engineered
cysteines which form disulfide bond thus increasing the dimer population. In contrast, the
FT-HT-Xa/Rho-Xa receptor showed a prominent monomer band and weak dimer signal,
as observed for FT-HT-Xa expressed alone. As seen in right panel of figure 17, using the
anti-Rho antibody, only dimerized receptors were observed for the M294C-Rho receptor,
which indicates that Ste2p did indeed homo-dimerize. These results and the cross-linking
results demonstrate the proximal location of the residues (L289-M294) on the
intracellular parts of the TM7 domains of two Ste2p molecules, and provide evidence for
homo-dimerization of Ste2p involving TM7 as well as TM1. The finding that six
consecutive residues in TM7, with the exception of P290C, showed an increase in
dimerization was unexpected since this region is believed to be α-helical. To see whether
dimerization would occur throughout TM7, we expanded Cys replacement to include the
full TM7 by generating eleven additional cysteine mutants N-terminal to the L289
residue (T278C, T279C, V280C, A281C, T282C, L283C, L284C, A285C, V286C,
L287C, and S288C) and two cysteine mutants C-terminal to the M294 residue (W295C
and A296C). Membranes from each mutant were prepared and processed with or without
Cu-P treatment. Compared to the Cys-less FT-HT-Xa receptor, the T278C and A285C
receptors exhibited at least a 3-fold increase in dimerization (Fig. 18). Though dimer
formation on T278C mutant was not observed in a recent study [21], this mutant showed
strong dimer formation with Cu-P treatment in our study. The difference observed for this
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Figure 16 Protease Factor Xa digestions of single cysteine containing Ste2p
receptors
A. Diagram showing possible explanation for ~66 kDa band from TM7-TM7 interaction.
B. Total membrane proteins derived from cells expressing indicated receptors. Cu-P
treated membranes with Ste2p containing single Cys mutations at various positions as
indicated were treated with Factor Xa as described in the Methods. The digests were
subjected to SDS-PAGE under reducing or non-reducing conditions, immunoblotted and
probed by anti-FLAG antibody.
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Figure 17 Pull-down assay
Total membrane was prepared from cells co-expressing differentially tagged receptors as
indicated. Following treatment with or without Cu-P, samples were immunobloted with
anti-Ste2p antibody (Left panel) or anti-Rho antibody (Right panel). The upper band
(~110 kDa) represents dimerized receptor and the lower band (~55 kDa) represents
monomer.
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one residue is likely the result of variations in experimental design. In our current study
Cu-P was used at a final concentration of 2.5 µM, while in the previous study the
concentration was 500 µM. In addition, in our study we used membrane preparations
whereas whole cells were used by Wang et al [21]. Receptors W295C and A296C
showed a large increase in dimerization upon treatment with Cu-P compared to FT-HTXa, (Fig 18; Table 9). In contrast, nine mutants (T279C-L284C, V286C, L287C and
S288C) gave virtually identical dimerization results in the presence and absence of the
oxidizing agent (Fig. 18; Table 9). Again NEM (N-ethylmaleimide) pre-treatment
completely eliminated the Cu-P mediated dimerization (Fig. 18C). These results indicate
that unlike the residues C-terminal to Pro290, residues located N-terminal to Pro290
exhibit a periodicity with respect to dimer formation of Cys mutants which is consistent
with the α-helical structure predicted for typical transmembrane domains of GPCRs.
Because of a concern that disulfide crosslinking might trap and thereby favor the
accumulation of dimer during the 30 min oxidization reaction, we analyzed the efficiency
of the dimer formation at different times (Fig. 19). The results indicated that L291C,
S292C, S293C, M294C, and W295C started to form dimers after 45 seconds of Cu-P
incubation and reached half maximum levels within 5 minutes. Previously, the relative
distance between TM residues in rhodopsin was estimated by the reaction time for
disulfide formation between to Cys residues on different TMs [52]. Thus, our data
indicate that TM7 C-terminal to P290 is highly flexible allowing all of the residues in this
part of TM7 to form disulfide bonds with more or less the same rapidity.

124

Effect of Ligand Addition on Dimerization
It is generally believed that activation of GPCRs upon ligand binding results in a
conformational change involving rearrangement of transmembrane domains [53-56]. To
ascertain whether this conformational change would affect Ste2p dimerization, we
investigated the changes in the dimerization pattern of Ste2p receptors in the presence
and absence of ligand. The membranes expressing each mutant receptor were incubated
with agonist (α-factor) or an antagonist ([desW1, desH2] α -factor) and then treated with
Cu-P. Dimer and monomer formation were monitored by western blots (Fig. 20A and
20B) and the ratio of dimer to monomer was determined (see Methods, Table 9). Dimer
formation of the Cys-less FT-HT-Xa receptor in the presence or absence of Cu-P was not
affected by agonist or antagonist (Fig.20A and Table 9). Also, the ratio of dimer to
monomer formed by Cu-P mediated cross-linking of the TM1 cysteine mutants did not
change significantly after incubation with α-factor or α-factor antagonist (representative
results for V68C is shown in Fig. 20B and Table 9). A time course of crosslinking at 0.75,
2, 5, 10, 20, and 30 min was also performed with the V68C receptor incubated with either
α-factor or antagonist. The reaction was complete at 45 seconds (0.75 min) and no
change in crosslinking relative to that observed in the absence of ligand was observed
(Fig. 21). TM7 mutants which did not exhibit increased levels of dimerization upon Cu-P
treatment (T279C-L284C, V286C, L287C and S288C), also showed no difference in
dimer formation in the presence of α -factor or antagonist (representative results for
S288C is shown in Fig. 20B Table 9). However, for those TM7 receptors which exhibited
significant increase in dimer formation upon Cu-P treatment (A285C, L289C, L291C,
S292C, S293C, M294C, W295C, and A296C), α-factor treatment decreased the relative
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amount of dimer formation (representative results for T278C and W295C are shown in
Fig. 20B and Table 9). Taken together, the dimer interface of TM7 of Ste2p changed in
response to either agonist or antagonist binding.
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Figure 18 Effect of Cu-P (Cu (II)-1, 10-phenanthroline) treatment on FT-HT-Xa
containing cysteine replacements in TM7
Membranes were prepared, treated without (A) or with (B) Cu-P reagent, solubilized and
separated on SDS-PAGE. Each sample was immunoblotted and probed with anti-FLAG
antibody. The upper band (~110 kDa) represents dimerized receptor and the lower band
(~55 kDa) represents monomer. C. Each indicated receptors were treated with Cu-P in the
presence of NEM (N-ethylmaleimide) added prior to Cu-P treatment.
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Figure 19 Time course analysis of dimer formation at the residues C-terminal to
P290 of TM7
Total membranes were prepared from cells expressing each receptors and treated with
Cu-P (Cu (II)-1, 10-phenanthroline) for 45 sec, 2 min, 5 min, 10 min, 20 min, and 30 min.
The samples were analyzed by SDS-PAGE, following by immunoblotting with antiFLAG antibody. The average percentage of dimer population from three independent
experiments was calculated and plotted.

129

Figure 20 Effect of ligand binding on Cu-P (Cu (II)-1, 10-phenanthroline)
stimulated disulfide bond formation
A, B. Total membrane protein was derived from cells expressing indicated receptors.
Each sample was immunoblotted and probed with anti-FLAG antibody. FT-HT-Xa
receptor was treated as indicated. B ‘-’ indicates no treatment, ‘+’ indicates Cu-P treated
samples, ‘α +’ indicates samples incubated with α-factor followed by Cu-P treatment and
‘A+’ indicates samples incubated with the antagonist, [desW1, desH2]α-factor, followed
by Cu-P treatment.
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Figure 21 Time course cross-linking of V68C
Total membranes were prepared from cells expressing V68C receptor and treated as
indicated. ‘Cu-P’ indicates Cu (II)-1, 10-phenanthroline (Cu-P) treated samples, ‘αfactor, Cu-P’ indicates samples incubated with α-factor followed by Cu-P treatment and
‘antagonist, Cu-P’ indicates samples incubated with the antagonist [desW1, desH2] α factor followed by Cu-P treatment. Cross-linking was terminated at 45 sec, 2 min, 5 min,
10 min, 20 min, and 30 min. The samples were analyzed by SDS-PAGE, following by
immunoblotting with anti-FLAG antibody. The upper band (~110 kDa) represents
dimerized receptor and the lower band (~55 kDa) represents monomer.
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CHAPTER 5 Discussion
In this study, using a disulfide cross-linking methodology, we identified a specific
residue in TM1 that interacts with itself in Ste2p dimers, and we present the first evidence
that residues in TM7 of this receptor participate in its dimerization. All of our studies
were conducted with Ste2p in its membrane-bound state. Previously, it was shown that
the maximum distance between α-carbons linked by disulfide bonds is about 7Å [57].
Thus, cross-linking experiments should identify amino acid side chains that are in close
proximity when using the Cu-P oxidation reagent, which facilitates oxidation of
sulfhydryl groups in cysteine residues. In analyzing our data, it is important to note that
disulfide crosslinking might trap transient intermediates. Depending on the time of crosslinking relative to the rates of interconversion of the monomeric and dimeric states of the
receptor, covalent cross-linking might affect the equilibrium and bias the sample to yield
more dimeric species than are present in the native population of the receptor. However,
by comparing the cross-linked population of a receptor mutated in a specific region we
believe we can learn about the relative tendencies of individual residues to participate in
receptor-receptor contacts. Cross-linking between cysteine residues engineered into
GPCRs and the use of Cu-P as an oxidizing reagent to facilitate disulfide bond formation
between TMs in GPCRs has been used extensively by the Wess and Oprian laboratories
[48, 51, 55, 58, 59] and was recently applied to Ste2p dimerization [21].
It had been suggested that TM1 formed a component of the interface between the
two receptors in the Ste2p dimer [19, 21, 60]. Our results support these findings and
furthermore provide direct evidence for the involvement of V68 in TM1 in Ste2p
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dimerization. The mutant receptor V68C showed markedly increased dimerization over
that of the FT-HT-Xa after Cu-P treatment, while under identical conditions all of the
remaining TM1 Cys receptors showed at most a minor increase in dimer formation (Fig.
15A; Table 9). The ability of V68C to form dimers is in good agreement with the recently
published finding of a V45C-V45C cross-linking [21] since V45 and V68 are both
located on the same face of TM1 and on opposite ends of TM1 (Fig. 22A). It was
previously proposed that G56XXXG60 residues in TM1 of one GPCR monomer interacted
with a hydrophobic-rich surface of TM1 (perhaps involving residues I53, V57, A61, and
L64), on the second monomer by a kind of “groove-in-ridge” association with Gly being
the “groove” residues and the hydrophobic residues acting as the “ridges” [19]. In this
study, we found that V68C formed a disulfide bond. The fact that only one residue in the
sequence (L64T66L67I67V68M69) formed this linkage suggests that the Ste2p-Ste2p
interactions involving this region of the TM1 helix have significant spatial restrictions
and that the TM1 helix at the carboxyl side of the G56XXXG60 sequence may be
relatively rigid. We note that a biophysical analysis of TM1 in micelles indicates that the
G56XXXG60 motif itself is flexible [[61] and unpublished results] and may facilitate TMTM interactions between proximal helical elements. In any event our mutational analysis
of the TM1 domain defines a specific residue (V68) that appears to be involved in Ste2p
dimerization. In a previous FRET analysis, Overton and Blumer [60] analyzed the
transmembrane domains of Ste2p that are involved in dimerization by expressing various
combinations of Ste2p fragments. They concluded that TM1 is necessary and probably
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Figure 22 Dimerization interfaces of Ste2p
A. V68 (red), a dimer contact found in the current study, is located on the same plane
with V45 (green) a dimer contact at the extracelluar end of TM1 [21]. The backbones of
two glycine residues (blue) known to play a role in Ste2p dimerization are shown. Two
residues (F55, R58) involved in ligand binding are presented as a stick model located on
the opposite side of the dimer interface. B. TM7/TM7 dimer interface. The backbones of
three dimer contacts identified from the current study (T278, A285 and L289, from top to
bottom) are colored green. A281 (light gray) and T282 (red) would appear to be
candidates for dimer contact based on a sideview of TM7 (Fig. 23A), but the model here
shows that alignments of these two residues are not favorable for disulfide bond
formation. C. Proposed oligomerization interfaces of Ste2p. Dimerization of Ste2p
involving TM1/TM1 (magenta) and/or TM7/TM7 (yellow) interface allows TM4/TM4
interface (dark grey) to mediate a new dimerization contact enabling oligomerization. An
extracellular view of a representative trimer is shown.
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sufficient for dimerization, although they speculated that the N-terminus and TM2 may
contribute to stabilize the dimers. However, our disulfide cross-linking data
demonstrated that TM7 is also involved in the interface for dimerization of Ste2p. In the
present study we have analyzed full-length receptors and it is possible that the fusion of
fluorescent protein at the C-terminal of truncated receptors in the previous FRET studies
hampered the interactions between TM7 domains. The involvement of TM7 in dimer
formation is consistent with our previous observation that a TM6-TM7 fragment of Ste2p
runs as a dimer in SDS-PAGE gel [62].
The finding that TM7 residues are involved in Ste2p dimerization leads us to
propose that at least three dimerization interfaces can exist in Ste2p. In addition to the
TM1 and TM4 interfaces previously found [21, 60], our data suggests that TM7-TM7
interactions are also involved in direct contacts in the Ste2p dimer. Since TM1-TM1 and
TM4-TM4 contacts have been previously suggested to be involved in higher order
oligomers [21] and a Ste2p trimer was demonstrated by crosslinking in a gel and by
atomic force microscopy [40] it is possible that in a single receptor can interact
simultaneously with two additional receptors with different interfaces between the
monomers: TM7 and/or TM1 can interact with TM7 and/or TM1 of a second receptor,
while TM4 can interact with TM4 of a third receptor to form oligomers. A representation
of a trimer is shown in Fig. 22C. With higher oligomers envisaged to contain additional
interactions. Based on the existing experimental data it is not possible to conclude
whether TM1-TM1 and TM7-TM7 dimers can be formed simultaneously in the cell. The
results described in this study show that cysteine residues introduced in positions T278,
A285 and L289 on the extracellular half of TM7 form a disulfide bond with their
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counterpart in another Ste2p monomer (Fig. 23A). This finding provides valuable
information relating to the arrangement of the TM bundles of Ste2p and allow us to
present a helical wheel projection of TM7 (Fig. 23B) in which these three residues are
oriented outward instead of facing inside the TM bundles as proposed previously in the
Ste2p model based on rhodopsin [35]. A281 and T282, which in a two dimensional
representation (Fig. 23A, 23B) appear to lie on the same helix face, do not form dimers.
However, our 3D model suggests that A281 and T282 are not close enough to form
disulfide bonds when replaced by Cys as illustrated in the modified model (Fig. 22B).
Therefore, the dimerization mediated by T278, A285, and L289 is consistent with the
alpha-helical periodicity in TM7 that continues up to Pro 290. In the absence of a crystal
structure for Ste2p, the disulfide crosslinking results contributes to understanding
structural features of the functional receptor such as inter-helical interactions that may be
involved in oligomerization.
In contrast to the specific pattern of residues which could participate in crosslinking in the portion of TM7 most adjacent to the extracellular surface, when the
engineered cysteine residues were located at the intracellular end of the TM7, C-terminal
to Pro290 which creates a kink in TM7, all residues were able to form disulfide bonds
(Fig. 23A) implying an absence of an ordered structure. We do not believe that the
experimental protocol, specifically the use of the oxidizing agent, leads to a global
denaturation of Ste2p because native cysteine residues in TM1 (C59) and TM5 (C252)
did not form an inter-GPCR disulfide linkage under the same experimental conditions
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Figure 23 Representation of cross-linking results of TM7 and helical wheel
presentation of TM1 and TM7 in Ste2p
A. Summary of TM7 cysteine cross-linking results. The horizontal lines represent the
boundary of the cell membrane. Residues indicated by a circle filled in gray when
mutated to Cys are involved in dimer formation, whereas those residues shown in a box
do not form disulfide bonds. Residues marked by an * compensate for the non-functional
Y266C mutation. B. Helical wheel presentation of TM1 and TM7. Residues indicated by
a circle filled in gray are involved in dimer formation as found in this study. Residues
marked by an X are important for ligand binding.
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(Fig. 15B). Additionally, only one of the TM1 cysteine mutants formed Ste2p dimers and
only three residues out of twelve in the extracellular part of the TM7 showed increased
dimerization. Rather we propose that the L291-W295 region of Ste2p may be flexible
enough to allow these residues to be exposed for disulfide bond formation with their
counterpart in a second Ste2p monomer. Proline residues disrupt hydrogen bonding and
have been shown to twist the standard structure of helices by introducing a kink between
the segments contiguous with each other and to form molecular hinges [41, 63]. The
dynamic nature of the residues at the carboxyl side of Pro290 is consistent with the
results of a high resolution analysis of a 73 residue fragment of Ste2p in DPC micelles
which indicated that the Pro290 resulted in a kinked helix in this membrane mimetic
environment [64]. An irregular helical structure in part of a TM has been documented in
the crystal structures of other GPCRs. In rhodopsin, TM7 contains a helical segment near
the extracellular face of the receptor, followed by a non-helical segment in the vicinity of
P303 [36]. The crystal structure of the beta-adrenergic receptor also indicates the
presence of a short extended area in TM7 [65]. In addition, it has been proposed, using
computational simulations of the NPXXY motif, that this region was not an ideal alpha
helical structure [66]. Thus, there is precedent to propose that the part of TM7 in Ste2p
that is near the cytoplasmic membrane interface is not helical in structure. Although there
is a possibility that the residues C-terminal to Pro290 are not in the transmembrane
domain, this is unlikely because a previous study [42] and our cysteine accessibility
results for these residues, strongly suggested that W295 and A296 are the boundary
between TM7 and the intracellular space (Fig. 24 and Table 11). Obviously, nonhydrogen bonded elements of a peptide in a membrane represent a high energy state
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Figure 24 Cysteine labeling of selected mutants
Membranes were prepared from cells expressing each receptors and treated with
MTSEA-biotin or non-treated as indicated. Then, the samples were analyzed by SDSPAGE, following by immunoblotting with anti-FLAG antibody.
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Table 11 Cysteine labeling of selected mutants
Residue

% of MTSEA biotin labeling1

T199C

100

L291C

22.5

M294C

37

W295C

40

A296C

63

1

Labeling was expressed as a percentage of accessibility for each individual mutant after

normalization with T199C accessibility (=100%) as described in the Experimental
Procedures
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and it is possible that critical water molecules satisfy some of the required interactions for
Ste2p. Water molecules that bridge various receptor regions have been implicated in the
crystal structure of other GPCRs [36, 65]. Their involvement in the structure of Ste2p
must await a high resolution structure of this GPCR.
It has been observed that the homo-dimer interface of the dopamine D2 receptor
can be altered upon ligand binding [50]. To monitor possible ligand-induced
conformational changes in Ste2p dimerization, membrane samples were incubated with
either agonist or antagonist followed by Cu-P treatment. TM1 mutants showed similar
degrees of dimer formation in the presence or absence of ligand, which is consistent with
a recent study showing that dimer formation of V45C at TM1 was insensitive to α-factor
treatment [21]. In contrast, both agonist and antagonist treatment led to a decrease in the
level of dimer formed by TM7-TM7 interaction indicating that ligand binding caused a
conformational change in this region. In addition to a conformational change inTM7
induced by ligand binding, we can not rule out changes elsewhere in Ste2p upon ligand
binding that affects dimer formation.
The effect of ligand binding on TM7-mediated dimer formation suggests that
resting state dimers and activated state dimers involve different TM arrangements.
Previously it was shown that the ratio of monomer to dimer did not change in the
presence of ligand in Ste2p as tested by FRET [17]. Thus, it is possible that the
equilibrium distribution between monomer-dimer is maintained during receptor
activation, even while the dimer interface may differ. In addition, a recent study of the
serotonin 5HT2c receptor demonstrated that ligand binding induces a differential effect
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on the dimer interfaces. While the TM1/TM1 interface was insensitive to ligand
treatment, the TM4/5 interface changed during receptor activation [67].
Interestingly, a number mutations of residues (V276, V280, A281, T282, and
L284) which compensated for the activity of the signaling defective mutant receptor
Y266C are clustered at the extracellular portion of the TM7 (Fig. 23A, TM7 residues
labeled as *)[68]. The cluster of compensatory mutations at the extracellular part of TM7
indicates that this region is important for receptor activation. The decrease in dimer
formation at TM7 after ligand binding that we showed for T278C and A285C, both
located in the extracellular part of TM7, also suggest a conformational change in this
portion of Ste2p. In addition, two residues in TM1 (M54 and F55) were also identified
[68] as compensatory mutations for Y266C. Residues F55 and R58 are known to be
ligand contact sites and M54 is adjacent to F55 [23, 69]. Therefore, the extracellular ends
of TM1 and TM7 may play a key role in initiating receptor activation after ligand binding
to TM1 and the subsequent conformational change of TM7 may facilitate the receptor to
adopt a fully activated state. Thus, the regions of the receptor that experience changes in
the formation of dimers upon ligand binding might be important for the activation
mechanism. Many GPCRs assume different conformations in their active and inactive
states, and it is widely accepted that GPCRs sample many states even when occupied by
ligand [for review see [70]]. Under our experimental conditions Cu-P mediated disulfide
formation appears to distinguish these different conformations, possibly implicating a
change of the dimer interface as part of the receptor activation mechanism.
The similar effects of agonist and antagonist binding on disulfide formation
involving residues in the TM7 dimer interface can be understood in terms of distinct
145

binding and signaling domains for α-factor [71]. Extensive structure-function analysis of
α-factor and Ste2p has revealed that the N-terminus of α-factor has a role in activating
the receptor while the C-terminus is critical for receptor binding. Since agonist
(WHWLQLKPGQPNleY) and antagonist (WLQLKPGQPNleY) are very similar (10
identical residues out of 13 ), and both ligands compete with each other with high affinity
in binding to Ste2p, it is reasonable to suppose that the binding sites of both ligands in the
receptor are highly overlapping especially at the C-terminal end of the ligands. Moreover,
we believe that ligand binding is a multi-step process in which the carboxyl terminus of
α-factor and α-factor antagonists bind first and then several conformational changes
occur along the activation pathway [72, 73]. Finally, the carboxyl terminus has been
shown to interact with residues in TM1 [23, 73]. Based on this understanding it is not
unreasonable that both agonists and antagonists first bind to TM1 promoting changes in
the conformation of both TM1 and of TM7, which is next to TM1 in the tertiary structure
of Ste2p. These conformational changes apparently restrict disulfide formation at the
TM7 dimerization interface between Ste2p monomers except the region between the
boundary of TM7 and cytoplasmic tail.
Much remains to be understood concerning the significance of GPCR
dimerization in the signaling process. The residues in TM7 examined in this study,
S288LPLSSMWA296, are highly conserved in Class D receptors and are considered to
have a similar function to the NPXXY residues in Class A receptors [35]. In Class A
receptors, the NPXXY motif is regarded to be important for receptor activation. For
example, mutations in this motif affected receptor expression, ligand affinity, receptor
sequestration, and heterotrimeric G protein coupling [74-77]. It is possible that TM7
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plays an important role in both receptor activation and dimerization in Ste2p and in other
GPCRs as well, and that dimerization is linked to signaling by these ubiquitous proteins.
The results presented herein provide residue level information concerning the proximity
of different sites on two Ste2p monomers in their native membrane environment. The
physiological relevance of this information and of dimerization in GPCRs continues to be
an intriguing area of GPCR biology.
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Part IV Participation of the Ste2p N-terminus in Homo-Dimer
Formation and the Effect of Ligand Binding on this Interaction
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CHAPTER 1 Introduction
The structural hallmark of GPCRs is their seven membrane-spanning domains
connected by extracellular and intracellular loops, oriented such that the N terminus is
outside of the cell and the C terminus is inside. As discussed in the part I, GPCRs sense
signals in the extracellular environment. Ligand binding to its cognate GPCR promotes a
conformational change in the receptor and triggers signal transduction. As the receptor
goes through the activation mechanism, it is well known that movement of the
transmembrane domains are involved in the change of conformation [1], [2-6]. It is
expected that concurrent changes in conformation also occur in the N-terminus and
extracellular loops of the receptor, though limited structural information is available for
these regions.
Using the substituted cysteine accessibility method (SCAM) [7] our lab found that
the first extracellular loop (EL1) of the α-factor receptor has a tertiary structure that limits
solvent accessibility to some residues, and this accessibility changes in a liganddependent manner presumably through induced conformation changes. SCAM analysis is
being used currently in our lab to study the accessibility of residues of the N-terminus of
Ste2p. During these analyses it was noted that the N-terminal mutant Y26C promotes
receptor dimerization under both reducing and non-reducing conditions. This observation
stimulated the investigation into whether other N-terminal residues participate in the
dimerization of Ste2p, as was observed for residues in TM1 and TM7 (Part 3,
Dissertation). In the Class C group of GPCRs, it has been established that a motif
known as the Venus fly trap (VFT) at the N-terminus, and cysteine-rich domains (CRDs),
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localized between VFT and transmembrane domains are important for dimerization of
this receptor class [8, 9] [10-13]. Thus there is a precedent for the involvement of Nterminal residues in GPCR dimerization.
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CHAPTER 2 Experimental procedures

Strains, Media, and Plasmids
The Saccharomyces cerevisiae strain BJS21 was used in all assays [7]. The
relevant genotype is MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 ste2::KanR.
For disulfide cross-linking, yeast strain BJS21 (ste2-deletion strain) bearing each fifteen
different single cys mutants ranging from Gln20 through Ser34 of N-terminus of Ste2p
were given from Seraj Uddin (at UT knoxville). Cells were grown in the absence of
tryptophan on MLT medium [7]. All media components were obtained from Difco and
were of the highest quality available.
Preparation of membranes
Membrane preparation of Ste2p was carried out essentially as described
previously [14]. Cells were grown to log phase, and then 1 x 108 cells were harvested by
centrifugation and lysed by agitation with glass beads in a lysis buffer containing 50 mM
Hepes, pH 7.5, 1 mM EDTA, 10 µg/ml phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin,
and 2 µg/ml pepstatin. The lysate was cleared by centrifugation at 2,000 x g for 5 min,
and then membranes were harvested by centrifugation at 15,000 x g for 45 min. The
membrane pellet was washed and then resuspended in 100 µl of a buffer (pH 7.4)
containing 10% glycerol, 50mM Hepes, 0.15mM NaCl, 2mM CaCl2, 5mM KCl, 5mM
MgCl2, 4mM EDTA [14]. The protein concentration was determined by the Lowry assay
(Pierce), and the membrane preparation was stored at -20 ºC overnight and used for
further assay the next day.
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Disulfide Cross-linking with Cu-Phenanthroline
The 100 µg of membrane protein preparation were treated with a fresh preparation
(pH 7.4) of Cu (II)-1,10-phenanthroline (CuP; final concentration, 2.5 µM CuSO4 and
7.5µM phenanthroline). The reaction was carried out at room temperature for 30 min,
terminated with 50 mM EDTA and kept on ice for 20 min followed by adding Laemmli
sample buffer. In experiments designed to prevent disulfide bond formation, the
membranes were treated with 5mM of NEM for 20min prior to incubation with Cu-P
reagent. α-factor or antagonist,[desW1,desH2]α-factor (10 µM final concentration), were
added to the membrane preparation and incubation allowed to proceed for 30 min prior to
Cu-P treatment in experiments performed to examine the influence of ligand on
dimerization

Western blot
Immunoblot analysis of Ste2p was carried out as described previously [14]. Each
sample was incubated at room temperature and then separated on NuPAGE 10% Bis-Tris
SDS-polyacrylamide gel (Invitrogen) using either non-reducing or reducing conditions
and electrophoretically transferred to ImmobilonTM-P membrane (Millipore Corp.,
Bedford, MA). The blot was probed with anti-FLAG M2 antibody (Eastman Kodak Co.)
and the bands were visualized with the West Pico chemiluminescent detection system
(Pierce).

162

CHAPTER 3 Results
Cells expressing each of the different Cys mutants were grown and membranes
were prepared. The samples were analyzed by SDS-PAGE and probed with anti-FLAG
antibody (Fig. 25). In general, all mutants showed higher dimer formation than WT under
non-reducing conditions without Cu-P treatment (Fig. 25A and Fig. 26). About 20% of
the WT receptor was in the dimer form under conditions that we showed previously (Part
III, Dissertation) was due to non-disulfide mediated, inter-molecular interactions,
whereas from 30 to 90 % of the mutant receptors were in the dimer form (Fig. 26). Nine
mutants (G21C, T23C, N25C, T27C, I29C, G31C, N32C, G33C, and S34C) showed a
small increase in dimerization (ranging from 1.3 ~ 1.8 fold) in comparison to WT (Fig.
25A and Fig. 26). Six Cys mutants, Q20C, S22C, I24C, Y26C, S28C, and Y30C, showed
a large increase in the dimer population relative to the monomer receptor (Fig. 25A and
Fig 26).
Under reducing conditions (data not shown, results from Seraj Uddin, a student in
the Becker Lab), the percentage of dimer for all Cys mutants, except Y26C, dropped to
that of WT indicating that these dimers were formed via disulfide bonds between the
mutated Cys residues. The fact that the Y26C dimer was not affected by reducing
conditions indicated that this unique dimer was formed by a non-disulfide interaction.
Mutation of the residue might lead to increased non-covalent interactions between
residues on two Ste2p molecules resulting in dimerization of the receptor.
N25C and T27C receptors showed different band patterns compared to WT (Fig.
25A). When analyzed by SDS-PAGE, WT Ste2p migrates as a group of three bands,
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consisting of the two major glycosylated forms of Ste2p along with the lower molecular
weight unglycosylated form (see WT lane, Fig. 25A). N25 and T27 are known to be
within the motif of N-linked glycosylation (Asn-X-Ser/Thr) of the receptor [15]. Thus,
substitution of these residues to Cys decreased heterogeneity of the glycosylated
receptors leading to a more prominent lower molecular weight band which is the nonglycosylated form of Ste2p and a concomitant lesser amount of higher molecular weight
band(s). While N32C and S34C also are within an N-linked glycosylation motif, there
were no readily observable differences with these two mutants with respect to WT (Fig.
25A).
It was possible that disulfide bonds were prevented from forming in some mutants
due to the environment of the Cys residue. Addition of Cu-P to provide a more oxidative
environment that facilitates Cys cross-linking has been used in many experiments to
determine Cys-Cys disulfide formation in membrane proteins [16-20]. Treatment of Cu-P
was performed with all fifteen N-terminal Cys mutants (Fig 25B). Nine mutants (Q20C,
G21C, T23C, Y26C, and from Y30C through S34C) were not affected by Cu-P treatment
(Fig. 25A, B, Fig. 27). However, three mutants (S22C, I24C, and S28C) exhibited
increased dimerization upon Cu-P treatment. In addition, three mutants (N25C, T27C,
and I29C) which in the previous experiment did not form dimers without Cu-P addition,
did dimerize in the presence of Cu-P.
To verify that this increase was due to disulfide bond formation, NEM
pretreatment was performed with the N25C, T27C and I29C mutants. NEM pretreatment
blocked dimerization for all three mutants (Fig. 25E), showing that the dimers were
indeed formed via a disulfide bond. These data suggest that the α-carbons of the two Cys
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residues are located close to each other, within 7 Å, the maximum distance to form a CuP mediated disulfide bond [21]. We did not observe any change in dimer ratio upon Cu-P
addition with the five mutants spanning residues Y30C to S34C, indicating that those
residues are not in close proximity (Fig 25A, B and Fig. 27).
It has been observed that ligand binding can induce a change in the receptor dimer
interface (this Dissertation, Part III) and [22, 23]. To examine the ligand effect on Cysmediated dimerization at the N-terminus, membranes were incubated with either α-factor
or [desW1desH2] α-factor (an antagonist) prior to Cu-P treatment. The dimerization of the
Q20C and Y26C mutants was not influenced by the presence of either ligand. In contrast,
the S22C mutant increased dimerization in the presence of Cu-P and α-factor or the
antagonist. While pre-incubation with α-factor did not affect the ratio of dimer for the
G21C, T23C and I24C mutants, antagonist pre-treatment of these three mutants resulted
in increased Cu-P dependent dimer formation (Fig.25 and Fig 27A).
The presence of ligand also altered the dimer population for the N25C, T27C, and
I29C mutants. These three mutants exhibited an increase in dimerization stimulated by
the presence of Cu-P. However, pre-treatment with α-factor prior to Cu-P treatment
blocked the formation of dimers for these mutants. In contrast, Cu-P stimulated
dimerization did occur with antagonist treatment. (Fig. 25C, D and Fig. 27B). These
results suggest that the N-terminus dimer interface is changed by ligand binding, with
different effects of agonist and antagonist. Once again, no change was observed in the
dimer ratio in the presence of agonist or antagonist for the five mutants spanning Y30C to
S34C, suggesting that these residues are not components of the dimer interface in the
resting or activated receptor (Fig. 25C, D and Fig. 27C).
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Figure 25 Dimer formation of Cys mutants
Membrane proteins untreated (A), treated with Cu-P (B), incubated with α-factor
followed by Cu-P (C), incubated with antagonist followed by Cu-P (D) or NEM added
prior to Cu-P (E) were analyzed by SDS-PAGE, then immunoblotted and probed with
anti-FLAG antibody. The upper band (~110 kDa) represents dimerized receptor
(indicated by a D) and the lower band (~55 kDa) represents monomer (indicated by a M).
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Figure 26 The percent of dimer formed by each Cys mutant
Membrane proteins were analyzed by SDS-PAGE, then immunoblotted and probed with
anti-FLAG antibody. The intensity of the monomer and dimer signal was measured by
densitometry and the ratio of the signals was determined. The percentage of dimer was
calculated as [Dimer/(Dimer+Monomer) x100].
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Figure 27 Effect of ligand binding on Cu-P [Cu (II)-1, 10-phenanthroline]
stimulated disulfide bond formation
Total membrane protein was prepared from cells expressing the indicated receptors: (A)
Q20C-I24C, (B) N25C-I29C. Each sample was immunoblotted and probed with antiFLAG antibody. Receptors were treated as indicated. ‘(-)’ indicates no treatment, ‘Cu-P’
indicates Cu-P treated samples, ‘α Cu-P’ indicates samples incubated with α-factor
followed by Cu-P treatment and ‘A Cu-P’ indicates samples incubated with the antagonist
[desW1, desH2]α-factor followed by Cu-P treatment. The intensity of the monomer and
dimer signal was measured by densitometry and the ratio of the signals was determined.
The percentage of dimer was calculated as [Dimer/(Dimer+Monomer) x100].
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CHAPTER 4 Discussion

In this study, we found that a part of the N-terminus participates in the formation
of a dimer interface. Within the N-terminus the sequence between residues 19 to 31 was
predicted to form a beta strand [24]. In this dissertation, residues were found that
increased dimerization in the absence of Cu-P upon mutation to Cys (Q20C, S22C, I24C,
Y26C, S28C, and Y30C). If these residues are localized on one side of the predicted beta
strand in the native Ste2p, then this may place them in position to interact with a
corresponding beta strand on a second Ste2p molecule. Residues G21, T23, N25, T27,
I29, and G31 are expected to be located on other side of the beta strand, and these
residues when replaced by Cys do not form dimers in the absence of Cu-P. As the
collision rate between the two thiols is dependent on the inter-residue distance [25, 26],
the odd-numbered residues may not be in close enough proximity to each other to form
effective disulfide bonds in the absence of Cu-P. However, dimers are formed in the
presence of Cu-P with N25C, T27C, and I29C. We believe that Cu-P functioned to
enhance dimerization by providing a more oxidative environment that facilitated disulfide
bond formation. We postulate that these receptors are impaired in their glycosylation due
to mutation (N25c and T27C) in the N-X-T/S motif or a mutation (I29C) that affected
glycosylation. The lowered glycosylation allows these residues to be in close enough
proximity to react when Cu-P is present. This hypothesis needs to be tested by
determination of the glycosylation state of these mutant receptors. We did not observe
high levels of dimerization for residues N32C, G33C, or S34C in either the presence or
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absence of Cu-P. Residues N32, G33, and S34 are not part of the predicted beta strand,
therefore the region containing these residues might not be in close enough proximity to
cross-link well. They showed only a small increase (1.5 fold or less) in dimer population
with or without Cu-P.
Prior incubation with α-factor prevented the Cu-P induced increase in
dimerization for the N25C, T27C, and I29C mutants, indicating a ligand-dependent
change occurred in this region. In contrast, treatment with antagonist, which binds but
does not activate the receptor, did not prevent the Cu-P-mediated dimer increase. Alphafactor binding to the receptor may alter the position of this region of the N-terminus, or
cause a distortion in the beta strand which makes the residues unable to interact and form
a disulfide bond. Interestingly, the G21C and T23C receptors, which do not form dimers
in the presence or absence of α-factor, did display an increased dimer formation in the
presence of antagonist. This indicates that the receptor adopts an intermediate
conformation between active and inactive state upon antagonist binding, which shifts the
G21 and T23 residues into a position favorable for dimer formation. Thus, although
phenotypically the antagonist binding maintains the receptor in the inactive state,
antagonist can still influence receptor conformation. Taken together, the ligand dependent
change of the dimer interface provided significant evidence that the N-termimus of Ste2p
is structured and that this structure can be altered either directly in response to ligand
binding or indirectly as part of the receptor activation mechanism.

172

CHAPTER 5 Summary and Future direction
Summary
This dissertation reports the identification of homo-dimer interfaces for Ste2p, the
yeast α-factor receptor, a model system for mammalian GPCR peptide hormone receptors.
Information regarding ligand-induced change at the dimer interface is reported as well.
To identify the dimer interfaces, single cysteine substitutions were introduced into Ste2p,
and disulfide-mediated dimerization was assessed. It was determined that one specific
residue was involved in dimerization in transmembrane domain 1 (TM1) and 9 residues
were involved in dimers formed via TM7. Interestingly, for the TM7 mutant receptors the
formation of dimers decreased in the presence of α-factor, indicating that ligand binding
resulted in a conformational change in this domain. Based on these results, it was
proposed that the dimer interfaces may differ in the resting and the activated states of the
receptor. Furthermore, the pattern of dimer formation resulted in a re-evaluation of the
structure of TM7, indicating that the full TM7 did not behave as a perfect α-helix as
predicted by modeling. In addition, residues at N-terminus of Ste2p were also found to
participate in dimer formation and surprisingly, dimerization mediated through some of
these residues was influenced by the presence of ligands. Future experiments, suggested
below, are proposed to provide further details on the dimer structure-function relationship.
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Whole cell, In vivo, cross-linking
The study of dimer formation in this dissertation was done with receptors in
membrane preparations. While the receptors in membrane preparations still maintain
their native conformation, as determined by receptor binding affinity, whole cell crosslinking would be useful. For these experiments, cross-linking could be assessed in a
native, intact cell for residues that are exposed to the extracellular surface. Since we
found residues that form dimers at the N-terminus, which is external to the cell
membrane, it should be feasible to do in vivo cross-linking with Cu-P by using whole
cells expressing those mutants. Such an approach was used recently by Wang and
Konopka to identify residues involved in dimerization of Ste2p via the extracellular
extracellular surface of the receptor, although N-terminal residues were not investigated
[27]. The effect of whole cell cross-linking on the physiological function of the receptor
has not been examined in this dissertation and might shed new light on the biological
relevance of receptor dimerization. However, when testing the biological activity of the
receptor in an intact cell, the metal toxicity of Cu-P must be considered since copper is
toxic at high concentration [28]. We observed an orange discoloration of the cells after
prolonged incubation (1-2 hrs) with Cu-P at 2.5 µM. Thus, a future experiment should be
determination of concentration of Cu-P which allows cross-linking without toxicity.
Alternatively, a chemical cross-linker can be used for the in vivo studies in lieu of Cu-P.
Currently, many cross-linkers with a variety of characteristics are commercially available.
For example, Shi et al used succinimidyl trans-4-(maleimidylmethyl) cyclohexane-1carboxylate (SMCC) to demonstrate Ste2p dimer and trimer formation [29]. Another
common reagent used to explore protein-protein interactions are the bismaleimide
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crosslinkers, BMOE, BMB and BMH, used to specifically connect the thiol groups
between two Cys residues (Fig. 28) [30-32]. The use of cross-linkers to detect and
stabilize protein-protein interactions at the dimer interface in intact cells will contribute to
our understanding of dimer structure-function relationships. Furthermore, comparison of
results using whole cells with those obtained from membrane preparations will be useful
to determine how accurately results obtained with membrane preparations reflect those
obtained with the intact cell.
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Figure 28 Reaction of maleimide-activated compounds to sulfhydryls
(http://www.piercenet.com/Objects/View.cfm?type=File&ID=0796)
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Study of receptor function and dimer relationship
N-terminal mutants that spontaneously dimerize upon introduction of Cys are
good candidates to test for the relationship between dimer formation and receptor
function. We can compare the biological activities of those mutants to WT without
adding oxidizing reagents, which might affect the physiological function of the yeast cell
itself. Recently, Shi et al suggested that the N-terminal tail of Ste2p may have a role in
modulation of mating, specifically the fusion of the MATa and MATα cells [24]. They
found that deletion of the first 20 amino acids ( N20) of Ste2p led to a decrease in
mating efficiency, but had little impact on receptor mediated G1growth arrest. Thus the
mutant cells responded properly in the growth arrest assay, indicating that the signal was
transduced by the receptor, but the cells failed to physically fuse to form diploids. They
also performed targeted scanning mutagenesis and cysteine accessibility studies to
investigate the site specific functional contributions of N-terminus. In that study, they
identified two highly conserved hydrophobic residues, I24 and I29, involved in the
mating process. The mating activity associated with these sites was shown to be
independent of receptor mediated G1 arrest signaling. Interestingly, mutation of either
I24 or I29 to Cys dramatically dropped mating abilities of the mutants compared to
mutation to Ala. In our study I24C and I29C were found to dimerize more readily than
WT. It is possible that disulfide bond formation at these residues may inhibit the proper
conformational change necessary for mating ability but not growth arrest. Indeed, it has
been observed that the functions of the receptor can be separated. For example, Ste2pY266A mutant can bind ligand without triggering the MAPK pathway [33]. Though all
Cys mutants (of residues Q20C- S34C of the N-terminus) were found to retain normal
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function in the growth arrest assay (personal communication with Seraj Uddin at UT), the
mating ability of the dimerized mutants have not yet been tested. A comparison of mating
competence in WT Ste2p with the N-terminal Cys mutants will contribute to the
understanding of the possible roles for dimerization in this GPCR.

Relationship of Dimers to Glycosylation State of Ste2p
The two residues, N25 and T27, at the N-terminus, which form dimers upon Cu-P
treatment, are known to be within the motif for N-linked glycosylation (Asn-X-Ser/Thr)
of Ste2p. The role of N-glycosylation in the dimerization of GPCRs has been described
previously. In the β1-adrenergic receptor, the mutant N15A, which results in the
elimination of a glycosylation site, is functional but deficient in dimerization relative to
the wild-type receptor [34]. The roles of N-glycosylation in the dimerization of the
human Bradykinin B2 receptor were also examined. It was determined that Nglycosylation participated in stabilization of dimers [35]. For the epidermal growth factor
receptor, receptor-receptor self-association was also reported to be highly dependent on a
conformation induced by N-linked glycosylation [36].
While most GPCRs are known to be N-glycosylated, the functional effects of
glycosylation vary significantly from receptor to receptor [37], in Ste2p, the
nonglycosylated receptor (N25Q/N32Q) displayed normal growth arrest activity and
subcellular localization, indicating that glycosylation is not important for wild-type
receptor signaling activity [15]. To test whether N-glycosylation has any effect on dimer
formation of Ste2p, three forms of the receptor having zero, one or two N-glycosylation
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sites can be used as templates to carry residue-specific Cys mutations. Dimer formation
of the mutants in the glycosylation deficient and WT backgrounds can be compared via
Western blot analysis. Alternatively, Cys mutant and WT Ste2p can be compared with
respect to disulfide bond formation following treatment with enzymes, such as
Endoglycosidase H or PNGase F, which deglycosylate proteins.

Study for higher order oligomer of Ste2p
Recently, many studies have documented that various classes of GPCRs form
dimers and/or even higher order oligomers [38-41]. Consistent with this, TM1, TM4,
TM7 and the N-terminus were found to serve as dimer interfaces for Ste2p [27, 42]
leading us to propose the existence of higher-order oligomerization for Ste2p. It is
possible that a single receptor can interact simultaneously with two additional receptors,
by utilizing different dimer interfaces between the monomers: TM7 and/or TM1 can
interact with TM7 and/or TM1 of a second receptor, while TM4 can interact with TM4 of
a third receptor to form oligomers. Dimerization via the N-terminus can also occur with
either TM1 and/or TM7 interaction to form oligomers. To test this, double Cys mutants
containing one Cys in either TM1 or TM7 and another Cys in TM4 can be used. Crosslinking of receptors with Cys substituted simultaneously into both TM1/or TM7 and TM4
should lead to the formation higher order species that can be identified by 4-12% gradient
SDS-gels (personal communication, George Umanah of the Becker lab).
Another method that might be used to identify the intrinsic (non-disulfide
mediated) oligomerization of Ste2p is perfluoro-octanoic acid (PFO)-PAGE [43-46]. PFO
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is a mild detergent. Thus, it maintains interactions within protein oligomers and permits
assessment of the native quaternary structure of membrane proteins when it is used to
replace SDS in gel electrophoresis.
For in vivo testing, biophysical assays such as FRET and protein fragment
complementation assay [47] also can be used. Split fluorescent proteins are not
fluorescent when expressed alone, but when fused to proteins in close proximity, they
assemble, fluoresce and thus serve to report on molecular proximity. This method has
been applied to find higher oligomerization of D2 dopamine receptor. Taken together, all
of the methods described above may be used to document and understand further the
nature of dimer/ higher order oligomerization of Ste2p.
Investigation of dimer formation pattern of TM7 mutants in C-terminal tail truncated
Ste2p
It was observed that consecutive six TM7 residues (from L291 to A296) were all
involved in dimer formation of Ste2p in this study and we proposed that this cytoplasmic
end of TM7 may not be a typical α-helical structure. It is possible the junction between
TM7 and C- terminal tail may be loosend due to the protein interactions with the Cterminal tail of Ste2p which contains around 160 amino acids (~18.5 kDa). To test this,
Ste2p truncated at residue 304 can be used. Previously, it was shown that truncated Ste2p
was still fuctional and able to form dimers [48]. Single cysteine mutants from L291C to
A296C can be constructed in the truncated Ste2p and dimer formation patterns can be
compared with those of the full length Ste2p by same methods as performed in this study.
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